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SUMMARY 
 
 
Acute myeloid leukemias (AMLs) that harbor translocations involving the MLL gene on 
chromosome 11q23 generate fusion transcripts that give rise novel fusion proteins with 
potent oncogenic properties and capable to destabilize the normal transcriptional 
activities. MLL fusion oncoproteins have been shown to initiate leukemic transformation 
primarily by overexpression of a specific set of genes, including HOXA4, 5, 6, 7, 9, 10 
(overall defined as “HOXA-code” genes), MEIS1 (a cofactor of “HOXA-code” proteins) 
and MYB. It‘s well established that the majority of these genes are involved in normal 
programs of self-renewal, maintenance and proliferation of hematopoietic stem cells 
and early progenitors. Therefore is not surprise that the deregulation of the stemness 
genetic programs due to MLL fusion oncogenes is a crucial step for leukemic 
transformation. To identify new stemness genes involved in MLL-mediated 
transformation we performed gene set enrichments analysis (GSEA) using public 
database of geneset profiles of normal hematopoietic cells in a cohort of pediatric AML 
previously analyzed. These analyses identified a series of genes more highly expressed in 
MLL-rearranged AML including the well known HOXA9, HOXA5 and MEIS1, together 
with an apparently novel gene: ZNF521 or zinc finger protein 521  
ZNF521 encodes for a zinc finger protein and, like HOXA9, is strongly expressed by CD34+ 
hematopoietic stem cells and drastically decreases during differentiation. To evaluate 
the importance of ZNF521 in MLL-rearranged AML, we performed a series of functional 
and mechanistic studies to uncover the role of ZNF521 in MLL-rearranged cells. We used 
lentiviral vectors to silencing the ZNF521 and expression vectors to induce MLL-fusion 
proteins such as MLL-AF9. These studies, both in vitro and ex vivo, demonstrate that the 
growth inhibition, reduced clonogenicity and cell cycle arrest induced by ZNF521 
depletion is mediated through enhanced myeloid differentiation. Moreover, we 
demonstrate that ZNF521 is a direct target of MLL-fusion oncoproteins such as MLL-AF9 
and MLL-ENL.  
Collectively, these findings identify ZNF521 as critical effector of MLL fusion in 
leukemogenesis that might be targeted to overcome the differentiation block associated 
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with MLL-rearranged AML and thus highlight ZNF521 as potential therapeutic target in 
treating this subtype of aggressive leukemias 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
RIASSUNTO 
 
 
Il gene MLL è spesso coinvolto in traslocazioni cromosomiche che causano la formazione 
di nuovi trascritti di fusione in grado di codificare delle proteine chimeriche con elevate 
proprietà oncogeniche e di de-regolazione dell’attività trascrizionale. Le oncoproteine 
MLL di fusione sono capaci di iniziare la trasformazione leucemica provocando una 
overespressione di diversi geni, tra cui quelli più critici sono gli HOXA4-10 (che 
complessivamente costituiscono l’HOXA-code), MEIS1 (un cofattore delle proteine HOXA-
code) e MYB. La maggior parte di questi geni sono implicati nei normali programmi di 
self-renewal, mantenimento e proliferazione della popolazione cellulare ematopoietica 
staminale e dei progenitori. È evidente che la deregolazione dei programmi genetici 
associati alla staminalità, provocata dalla presenza degli oncongeni MLL di fusione, ha un 
ruolo cruciale nella trasformazione leucemica delle cellule ematopoietiche.  
In questo studio abbiamo identificato, tramite GSEA (Gene Set Enrichment Analysis), i 
profili genetici delle cellule CD133+ normali ottenuti da database pubblici e, 
successivamente abbiamo valutato la loro espressione in una serie di leucemie acute 
mieloidi (LAM) pediatriche precedentemente analizzate in altri studi di espressione 
genica. I risultati mostrano che tutti i target noti degli oncogeni MLL di fusione (HOXA, 
MEIS1) sono up-regolati esclusivamente nelle LAM con traslocazioni del gene MLL. 
Abbiamo inoltre osservato che tra i geni maggiormente  up-regolati è presente anche 
ZNF521, un gene che codifica per una proteina appartenente alla famiglia delle proteine 
zinc-fingers. Come HOXA9, anche ZNF521 è altamente espresso nelle cellule 
ematopoietiche staminali CD34+ e la sua espressione diminuisce rapidamente durante il 
differenziamento. Per valutare l’importanza di ZNF521 nelle LAM con traslocazioni del 
gene MLL abbiamo eseguito una serie di studi funzionali e meccanicistici in vitro ed ex 
vivo con cellule primarie, utilizzando sia vettori lentivirali per il silenziamento del gene 
ZNF521, sia vettori di espressione di diversi oncogeni con traslocazioni di MLL. Questi 
studi hanno dimostrato che il silenziamento di ZNF521, che ne determina una 
diminuzione di espressione ed induce le cellule a differenziare, causa un’inibizione della 
proliferazione cellulare, una drastica riduzione della clonogenicità e l’arresto del ciclo 
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cellulare in fase G1. Inoltre, abbiamo dimostrato che ZNF521 è tra i target diretti delle 
oncoproteine MLL di fusione, ed è quindi attivamente coinvolto nella trasformazione 
leucemica in seguito alle traslocazioni del gene MLL.  
In conclusione, ZNF521 si è rivelato essere un nuovo importante effettore degli oncogeni 
MLL di fusione e un fattore cruciale nel mantenimento dello stato indifferenziato delle 
cellule mieloidi leucemiche che presentano riarrangiamenti del gene MLL e potrebbe 
quindi dimostrarsi un importante nuovo target terapeutico. 
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INTRODUCTION 
 
 
1. HEMATOPOIESIS 
 
Hematopoiesis is the process that gives rise to all blood cellular components during 
embryonic development, and throughout adulthood to produce and replenish the 
hematopoietic system. It is estimated that this process provides to produce almost 1010 
cells every hour for replenish continuously aged or damaged blood cells (Williams, 1995). 
This system of generative activity is tightly regulated by progressive restriction of cell 
fate potentials initiating from hematopoietic stem cells (HSCs) to lineage-restricted 
progenitors that produce all lineages of mature blood cells (Figure 1).  
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Figure 1: Hematopoiesis. 
The figure shows the development of hematopoietic stem cells (HSC). All blood cells are derived from 
HSCs, which are at the basis of the adult blood cell differentiation hierarchy. HSCs can be subdivided into 
self-renewing HSCs and multipotent progenitors. These include common lymphoid progenitor (CLP) and 
common myeloid progenitor (CMP). CMP further divides to give rise to more differentiated progenitors, 
committed to granulocytes and macrophages (GMs), and megakaryocytes and erythroid cells (MEPs). CLP 
produces progenitors committed to T cells and B cells. Successive division and differentiation of these 
progenitors give rise to fully differentiated B- and T-cells. CMPs maturation generate neutrophils, 
eosinophils, basophils, monocytes, platelets and erythrocytes.  
 
Deregulation along the developmental pathway leads to various hematological disease 
like anemia, immunodeficiencies or leukemia. Therefore, a deeper knowledge of the 
mechanisms that finely regulate this balancing is pivotal for understanding of both 
normal hematopoietic development and pathogenesis of hematopoietic disease.  
All cellular blood components are derived during fetal and adult life through a 
mechanism that is conserved across vertebrates and involve two waves: the primitive 
wave and the definitive wave  (Galloway, 2003). The primitive wave, which involves an 
erythroid progenitor, gives rise to erythrocytes and macrophages during early embryonic 
development (Palis, 2001; Madhumita, 2013) and is predominantly marked by erythroid 
progenitor to produce red blood cells that facilitate tissue oxygenation during growing 
embryo (Orkin and Zon, 2008). The primitive wave is transitory, however, and these 
erythroid progenitors are not pluripotent and do not have renewal capability. By 
contrast, definitive hematopoiesis occurs later in development, notably at different time 
points in different species. In vertebrates, a definitive wave involves hematopoietic stem 
cells (HSCs) that originate in the aorta-gonad-mesonephros (AGM) region of the 
developing embryo. In humans, HSCs are produced in yolk sac and placenta from where 
they migrate to the fetal liver and then to the bone marrow, which is the location for 
HSCs in adults (Dzierzak, 2007; Cumano, 2007). 
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1.1. HSC: the paradigm of self-renewal and differentiation. 
 
The integrity of the hematopoietic system depends on a large number of blood cell 
lineages being continuously replenished from a rare population of pluripotent 
hematopoietic stem cells (HSCs), representing a paradigm for how multi-lineage diversity 
can be achieved from a common stem cell through lineage commitment and subsequent 
differentiation (Kondo, 2003). Hematopoiesis requires a continuous production of 
progenitors and mature blood cells from HSCs through differentiation processes. In fact, 
HSCs sustain lifelong production of all blood cell types through finely balanced divisions 
leading to self-renewal and differentiation. Differentiation is associated with a loss of 
self-renewal capacity, requiring HSCs as a population to self-renew to maintain itself. 
The fate choice of HSCs to either self-renew or differentiate is controlled by a complex 
interplay between intrinsic mechanisms and extrinsic signals from the surrounding 
environment or stem cell niches (Moore, 2006).  
Extrinsic (environmental) signals are predominantly derived from stromal cells and their 
products (Wineman, 1996; Blazsek, 1995). The marrow, in particular, contains specialized 
environments that regulate the balance of HSC self-renewal and differentiation and 
comprise what has been termed the stem cell niche. In fetal and adult mammals, HSCs 
predominantly reside in fetal liver (FL) and bone marrow (BM), respectively. However, 
HSCs do not originate in FL or BM, but rather migrate from other tissues to these sites 
during embryonic development. In mammals, most blood cells have relatively short 
lifespans. For this reason, HSCs continuously differentiate into multiple lineages of 
different blood cell types, simultaneously replicating themselves through self-renewal to 
prevent depletion of the stem cell pool in the BM. Nevertheless, external environmental 
signals must integrate with intrinsic molecular machinery to control the fate choices of 
individual HSCs. Such genetic mechanisms predetermine the behavior of HSCs and thus 
should limit the generation of HSC heterogeneity (Muller-Sieburg, 1996; Abkowitz, 1998; 
Chen, 2000). 
The changes in gene expression over the course of hematopoietic differentiation are 
profound and complex. The number of differentially expressed genes is similar within 
hematopoiesis and across human tissues, suggesting comparable complexity. In fact, cell 
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fate specification involves the action of primary lineage determinants (transcription 
factors, TF) that initiate and resolve mixed lineage patterns of gene expression by 
activating lineage appropriate genes and repressing alternate lineage genes (Laslo, 
2006). Knockouts or forced expression experiments on model organisms (e.g., mice, 
zebrafish, chicken, drosophila, xenopus) were performed to understand the functions of 
the critical transcription factors. In details, it is possible to see in Figure 2 the expression 
of the most important TF during the blood development. The knockdown of these genes 
leads to a block in differentiation, meaning a crucial role of the down-regulated gene, in 
the process of cell maturation 
 
 
 
Figure 2: Transcription Factors during blood cell development.  
Red bars indicate the stages at which hematopoietic development is blocked in the absence of a given 
transcription factor, as determined through conventional gene knockouts. Abbreviations: LT-HSC, long-
term hematopoietic stem cell; ST-HSC, short-term hematopoietic stem cell; CMP, common myeloid 
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progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, 
granulocyte/macrophage progenitor; RBCs, red blood cells. Figure adapted from  (Orkin and Zon, 2008) 
 
 
In the last years, many studies focused on the analysis of gene regulatory networks that 
direct cell fate decisions within the hematopoietic system. Gene disruption studies have 
shown that GATA-1 is necessary for erythroid and megakaryocyte development whereas 
PU.1 is required for the generation of myeloid (macrophage and granulocyte) and 
lymphoid lineages (Scott, 1994; Orkin, 1998). Based on the findings that PU.1 and GATA-
1 could inhibit each other’s molecular activities (Rekhtman, 1999; Zhang, 1999), it was 
proposed that this cross-antagonism is critical for generation of 
megakaryocyte/erythroid versus myeloid progenitors (Cantor, 2002).  
Runx1 is a member of the runt family of transcription factors and plays an important role 
in definitive hematopoiesis (Wang et al., 1996). Knockout experiments in mice reveal 
that ablation of Runx1 means losing definitive erythroid, myeloid and lymphoid cells, 
indicating its importance in definitive hematopoiesis. Runx1 knockdown also leads to a 
decrease in the expression of cmyb, which belongs to the myb family of proto-oncogenes 
(Kalev-Zylinska, 2002; Burns, 2005; Gering, 2005). Further experiments on zebrafish 
reveal the importance of other genes during hematopoietic development. In fact in an 
early stage of development, cells co-expressing tal1, gata2, lmo2, fli1 and etsrp, appear 
to be indispensable for both endothelial and hematopoietic differentiation (Paik, 2010). 
A remarkable feature of transcription factors in the hematopoietic system is that the 
majority are involved in chromosomal translocations or with somatic mutations in 
human hematopoietic malignancies. Furthermore, experimental manipulation of the 
genes for such factors in mice often promotes malignancy; in fact hematopoietic cell fate 
is tightly associated with the origins of leukemias. 
Although up to now, several studies have shown and unveiled many aspects concerning 
the molecular mechanisms regulating HSC self-renewal versus differentiation, but many 
other are still to be elucidate. 
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2. LEUKEMIA  
 
Leukemia is defined as cancer of the blood forming system and characterized by 
proliferation of abnormal white blood cells, not fully developed and called blast or 
leukemia cells in the bone marrow. 
As a result, there is a loss of hematopoietic function due to the lack of mature 
granulocytes and monocytes as well as decreased red blood cell and platelet production. 
These abnormal precursor cells are capable of proliferation and cell division, but lack the 
capacity to differentiate (Borer, 1989). Leukemia can be divided into an acute and 
chronic form; acute leukemias are characterized by the clonal expansion of 
hematopoietic progenitor cells caused by a maturation arrest combined with enhanced 
proliferation resulting in a fast increase of immature blood cells. In contrast, in chronic 
leukemia, abnormal blood cells have a slower expansion of terminally differentiated cells 
that can still execute their normal function. A further division can be made depending on 
the lineage of the progenitor cell that is affected. When the leukemia originates from a 
lymphoid progenitor cell, it is named a lymphocytic or lymphoblastic leukemia, and when 
it originates from the myeloid lineage, it is called a myeloid or myelogenous leukemia. 
This identifies the 4 major types of leukemia: acute myeloid leukemia (AML), acute 
lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic 
leukemia (CLL). In children, chronic leukemias are very rare, ALL comprises the largest 
part (75-80%), and AML accounts for 15-20% of pediatric leukemias (Cordell, 1999). 
 
 
2.1. Leukemia Stem Cell: an hallmark in AML 
 
For several years uncontrolled proliferation was considered the distinguishing property 
of any malignant disease. The definition of a cancer stem cell (CSCs) is based on its 
functional properties, that is a malignant cell that has the ability to self-renewal and also 
to differentiate into multiple cell types to recapitulate the cell populations of the original 
tissue  (Jondan, 2007).  
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The Cancer Stem Cell Model, also known as the Hierarchical Model proposes that tumors 
are hierarchically organized CSCs lying at the apex (Bonnet, 1997).In the cancer stem cell 
model, within the cancer population of the tumours there is a small subset of cancer 
cells, CSCs, which constitute a reservoir of self-sustaining cells with the exclusive ability 
to self-renew and maintain the tumor. Considering that. it is difficult to completely 
eradicate them during treatment, they have become an intriguing target for future 
cancer therapy.  
Much of the evidence about the cancer stem-cell hypothesis has come from studies in 
hematologic malignancies. First experimental evidence, suggesting the existence of 
Leukemic stem cells (LSCs), resulted from observations made almost 40 years ago: it was 
demonstared by Park and collaborator in the 1971 that only 1 out of 10,000-100,000 
mouse myeloma cells obtained from mouse ascites were able to form colonies in semi-
solid medium (Park, 1971). Similarly, human leukemia cells from AML patients also 
formed colonies at very low frequency suggesting the presence of a small number of 
LSCs within the bulk of leukemic blasts (Sabbath, 1985; Griffin, 1986). 
The first conclusive evidence for CSCs came in 1997. Bonnet and Dick isolated a 
subpopulation of leukemia cells that expressed surface marker CD34, but not CD38 
(Bonnet, 1997). The authors established that the CD34+/CD38− subpopulation is capable 
of initiating tumors in NOD/SCID mice that were histologically similar to the donor.  
(Bonnet, 1997; Lapidot, 1994).   
It has been demonstrated that only a small number of LSCs can restore themselves and 
maintain the disease, whereas the majority of leukemia cells are in a more mature state 
unable to initiate the disease. It is also known as LSCs share analogous processes of the 
self-renewal and somehow differentiation of normal stem cells (Krause, 2007). In 
particular, it was discovered that similar signaling pathways involved in the control of 
self-renewal of HSCs are also key elements maintaining stemness in LSCs. These 
pathways include the well-known PI3K/Akt/mTOR (Fransecky, 2015), Wnt/beta-catenin 
(Wang, 2010; Lento, 2013), Hedgehog (Mar, 2011; Irvine, 2012), NF-kB (Kagoya, 2014; 
Zhou, 2015), Notch (Liu, 2013) and Bcl-2 (Domen, 2000; Lagadinou, 2013).  
Although LSCs have the capacity for self-renewal and differentiation, evidence has shown 
that a substantial number of LSCs are found in a quiescent G0 phase (Guzman, 2001).  
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This could provide a possible reason for the failure of chemotherapeutics to eliminate 
LSCs as they commonly target rapidly cycling populations. 
In AML, the origin of LSCs can be the result of accumulation of genetic disorders. It has 
been rationally postulated that LSCs arise from HSCs as the result of accumulation of 
oncogenic mutations, based on the observation that stem cells persist for long periods 
and undergo a number of cell divisions increasing the likelihood to obtain the minimum 
number of mutations necessary for malignant transformation (Lapidot, 1994; Bonnet, 
1997; Warner, 2004). Alternatively, LSCs may also result from more differentiated 
progenitor cells that have reacquired the capacity for self-renewal and accumulated 
additional mutations for malignant transformation (Cozzio, 2003; Warner, 2004).  
The intensive molecular investigation over the past two decades has shed new light on a 
large number of recurrent genetic lesions that have been identified to be associated with 
different subtypes of leukemias.  
One of these aberrations can be attribute to MLL translocations. It is well documented 
that MLL gene rearrangements are able to transform myeloid non-self-renewing 
progenitor cells into LSCs in AML (Krivtsov, 2006; Passegue, 2006). In fact, generation of 
knock-in mouse models, as well as model of transduced BM experiments, has 
demonstrated how MLL fusion oncogenes are able to induce leukemic transformation in 
normal hematopoietic cells. First, Corral demonstrates that Mll–AF9 fusion knock-in 
mouse model, that constitutively expressed MLL-AF9, develops AML (Corral, 1996). 
Subsequently, Collins and colleagues developed a conditional knock-in model that 
produced Mll-Af9 by interchromosomal translocation, similar to the mechanism for 
translocation formation in human cells. This mouse model also had a propensity for 
leukemia development (Collins, 2000). A similar approach was used to develop a 
conditional Mll–Enl knock-in model, which also led to a rapid onset of AML (Forster, 
2003). Moreover, important insights into MLL fusion-mediated leukemia development 
came from a study that assessed leukemogenic transformation of committed myeloid 
progenitors by MLL–ENL (Cozzio, 2003). A particularly important aspect of this work was 
the demonstration that mouse myeloid leukemias can originate not only from HSCs but 
also from committed myeloid progenitors that have no inherent self-renewal 
capabilities. As GMPs (Granulocite-Macrophage Progenitors), similar to all committed 
myeloid progenitors, do not possess self-renewal activity (Na Nakorn, 2002), MLL–ENL 
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expression appears to be able to re-activate at least some aspects of hematopoietic cell 
self-renewal. Expression of MLL–AF9 in GMPs leads to leukemogenic transformation of 
GMPs to LSCs (Krivtsov, 2006; Somervaille, 2006). Intriguingly, C/EBPα is a key myeloid 
transcription factor, which is required for the formation of granulocytic monocytic 
progenitors (GMPs) during normal hematopoiesis (Zhang, 2004). Ohlsson and colleagues, 
comparing human MLL-rearranged AML and normal progenitors gene expression profiles 
identified C/EBPα as a putative collaborator in MLL-rearranged AML. They found that 
deletion of C/EBPα rendered murine hematopoietic progenitors completely resistant to 
MLL-ENL–induced leukemic transformation, whereas C/EBPα was dispensable in already 
established AMLs. This data show that C/EBPα collaborates with MLL-ENL to activate a 
group of genes that, together with Hoxa9 and Meis1, are responsible for the early events 
that transform normal hematopoietic cells into malignant cancer cells. (Ohlsson, 2014). 
Therefore, these observations open important questions regarding how the deregulation 
of some genes and transcription factors with a role in stemness may contribute to the 
leukemia. Furthermore, seen that the balance of self-renewal and commitment to 
differentiation is dramatically deregulated in leukemic cells a better understanding at the 
molecular mechanism will be a fundamental source for molecular-based therapies in the 
future.  
 
 
2.2 Characteristic of MLL-rearranged AML 
 
Leukemias harboring rearrangements that involved the MLL (Mixed Lineage Leukemia) 
gene on chromosome 11q23 possesses unique biological and clinical characteristics. 
Genetic alterations in the MLL gene are associated with more than 70% of infant 
leukemias, but are less frequent in older children leukemias. Approximately 10% of adult 
leukemias bears MLL-translocations and MLL-related translocations are also commonly 
observed in secondary acute leukemias after topoisomerase inhibitor treatment  (Felix 
CA, 1998). It is a disease characterized by an extremely dismal prognosis, in part due to 
its poor responses to the conventional therapeutic treatment, such as chemotherapy 
(Balgobind BV, 2011; Slany, 2009).  
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These aberrations juxtapose the amino-terminus of MLL with the C-terminus of the 
fusion partners, destroying the normal histone methyltransferase function of MLL adding 
the heterologous functions of the fusion partner (Figure 3). 
MLL rearrangements generate a large variety of oncogenic MLL fusion proteins. To date, 
more than 60 different fusion partners have been identified, among which the most 
common ones are nuclear proteins with transcriptional activating activity (Krivtsov, 2007; 
Monroe, 2010; Yokoyama AL, 2010). 
Wild Type (WT) MLL is a very large, 431 kDa protein with many different identified 
domains that mediate protein-DNA, protein-protein, or protein-RNA interactions. The 
MLL protein is proteolytically cleaved into an N- and a C-terminal fragment by the 
protease TASPASE1 (Hsieh, 2003). The MLL N-terminal fragment has a Menin binding 
region, 3 AT hooks, a repression domain, 4 PHD fingers, an atypical bromo-domain and a 
FYRN (Phenylalanine and Tyrosine Rich N-terminus) domain. The MLL C-terminal 
fragment has the transcriptional activation domain, a FYRC (Phenylalanine and Tyrosine 
Rich C-terminus domain).  
The chromosomal break point region is just before PHD. Hence the fusion protein 
contains a portion of MLL N-terminus through the repression domain fused in frame with 
a C-terminal partner protein fragment. The rest of the N-terminus (from the PHD finger 
region to the TASPASE1 cleavage site) and the whole of MLL-C fragment is deleted in the 
MLL fusion protein as shown in Figure x.  
Therefore, MLL fusions do not conserve the TASPASE1 cleavage site, which has been 
shown to cause resistance to cell cycle specific degradation (Liu, 2010). 
Nevertheless, the deleted regions are frequently, but not always, represented in the 
reciprocal translocation product. In addition, the MLL gene is also involved in other 
aberrations such as partial tandem duplications (PTD) that occur in nearly 8% of AML 
patients with normal cytogenetic features (Figure 3). 
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Figura 3: Structure of MLL fusions  and onco-MLL complex.  
 
 
Intriguingly, only six frequent partner proteins (AF4, AF9, ENL, AF10, ELL, AF6) constitute 
the bulk (>80%) of all clinical cases of MLL leukemia  (Meyer, 2009) (Table 1), whereas 
the remaining fusions proteins were cloned each from a few isolated, mostly adult 
patients. These MLL rearrangements can be classified into five groups, according to 
differences in cellular location and putative function (Table 1) (Krivtsov, 2007).  
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Table 1: Classification of MLL fusions. MLL rearranges with a large number of partner genes. Each 
rearrangement can be classified into 5 groups based on putative function and cellular location of the 
chimera. (Table rearranged from  Krivtsov, 2007) 
 
 
• The first group is characterized by fusion partner genes encoding the nuclear DNA-
binding proteins AF4 (ALL1 fused gene from chromosome 4), AF9, AF10, ENL 
(eleven nineteen leukemia gene) and ELL (eleven nineteen lysine-rich leukemia 
gene). Taken all together, these aberrations account for more than 80% of MLL 
translocation in leukemia patients.  
• The second group involves cytoplasmic proteins such as AF6, AFX, GAS7, EEN, AF1p 
and Eps15. These fusion partners are found in more than 10% MLL rearranged 
leukemias. The common feature of this group of protein is coiled-coil 
oligomerization domains that are important for their transformation potential  
(So, 2003).  
• The third group of fusion partners includes septins (SEPT2, SEPT5, SEPT6, SEPT9 and 
SEPT11), which are cytoplasmic proteins playing a role in mitosis and cytoskeletal 
structure  (Hall, 2004). This group characterize only the 2% of MLL associated 
leukemias. 
• The fourth group is characterized by the histone acetyltransferases p300 and CBP. 
MLL is fused with these proteins retaining histone acetyltransferase activity, 
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although TA domain, which mediates interaction of p300/CBP with wildtype MLL, 
does not exist in MLL fusions  (Ida, 1997; Hall, 2004). These MLL fusions are also 
observed in 2% of MLL associated leukemias.  
• The fifth group contains only MLL–partial tandem duplication (MLL–PTD). MLL–PTD 
results from a variable number of duplication of exons 5 to 12 that are inserted 
before exon 11 or 12. MLL–PTD is found in 4-7% normal karyotype AML patients 
and also often associated with trisomy 11 abnormality  (Shiah, 2002) 
Approximately 50% of pediatric AML cases with an MLL rearrangement consist of 
t(9;11)(p22;q23). The other 50% predominantly include t(6;11)(q27;q23), 
t(10;11)(p12;q23), t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) (Raimondi, 1999) as 
shown in Figure 4. 
 
 
 
 
 
Figure 4: The distribution of translocation partners of MLL in pediatric AML. More than 60 different 
fusion partners of MLL have been identified, however t(9;11)(p22;q23) is the most common translocation 
that occurs in MLL-rearranged AML, accounting more than 40% of cases. Other frequent rearrangements 
are caused by the translocation t(10;11)(p12;q23), t(6;11)(q27;q23), t(11;19)(q23;p13) and 
t(1;11)(q21;q23) accounting for 13, 5, 11 and 3% of cases, respectively. Figure from (Balgobind, 2011) 
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Interestingly, over 80% of human AML containing MLL-rearrangements exhibit strong 
expression of  
genes normally restricted to HSC including, HoxA7, HoxA9, HoxA10 and Meis1  (Afonja, 
2000; Ferrando, 2003; Lawrence, 1999). Some of them, generally genes highly expressed 
in human AML with MLL-AF9 translocation, have been demonstrated to regulate survival 
and self-renewal of LSCs (Faber, 2009; Wong, 2007). Among them, HoxA9 and Meis1 
represent the best-characterized MLL downstream target, which take part of a wider 
transcriptional program critical for self-renewal of MLL LSCs. Therefore, identification 
and functional characterization of target genes directly or indirectly regulated by MLL 
fusions, is pivotal to understand the origin of the MLL-related leukemia as well as the 
abnormal function of HSCs, which will be crucial in order to develop new molecular-
based therapies. 
 
 
3. MLL GENE IS REQUIRED DURING DEVELOPMENT AND 
HEMATOPOIESIS 
 
MLL is the mammalian homolog of the Drosophila protein found in trithorax and is a 
member of the evolutionarily conserved trithorax group (trxG) family of proteins that 
positively regulate gene transcription and act antagonistically to the Polycomb group 
(PcG) proteins (Djabali, 1992; Gu, 1992; Ringrose, 2004). It belongs to the MLL family of 
SET domain containing histone methyltransferases that methylates histone H3 on lysine 
4 (Milne, 2002; Shilatifard, 2012). The H3K4Me3 mark at gene promoters is associated 
with active transcription (Figure 5). In fact, MLL positively regulates the expression of 
target genes including multiple homeodomain (Hox) genes through H3K4 methylation of 
gene promoters (Milne, 2002). Hox genes are transcription factors that participate in the 
development of multiple tissues, including the hematopoietic system (Abramovich, 
2005). Mouse models have conclusively shown Mll to have a crucial role in the control of 
Hox gene expression and in the development of the axial skeleton and hematopoietic 
systems of mammals. In fact, homozygous deficiency for MLL results in early embryonic 
lethality at embryonic day 10.5 (E10.5), exhibiting multiple patterning defects, and 
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heterozygous deletion of MLL incurs homeotic transformation, indicating altered Hox 
gene expression (Yu, 1995; Yagi, 1998; Ayton, 2001). Other experiments on Mll-deficient 
mice demonstrated that ESCs without Mll were unable to differentiate into any 
hematopoietic cell types in adult animals or in the fetal liver (Ernst, 2004a). Moreover, 
Ernst and colleagues, using an in vitro system, have demonstrated that the block in 
hematopoietic development was accompanied by global reduction in Hox gene 
expression and could be rescued by the reintroduction of individual Hox genes (Ernst, 
2004). 
In other experiments conducted in adult mice, the conditional ablation of Mll 
demonstrated its critical role to maintain adult hematopoietic stem cells (McMahon, 
2007). Despite interaction with active transcription factors, MLL interacts also with 
multiple proteins that suppress gene expression, such as histone deacetylase 1 (HDAC1) 
and HDAC2, CYP33, PcG proteins PC2 and CTBP (Xia, 2003). 
Besides its known role in embryonic development and hematopoiesis, MLL also 
orchestrates cell cycle progression at least through regulating the expression of cyclins 
and CDK inhibitors (Milne, 2005-B; Xia, 2005; Takeda, 2006; Kotake, 2009). 
 
 
 
Figure 5: Structure of wild type MLL and the MLL complex. MLL is a very large, 431 kDa protein with many 
different identified domains that mediate protein-DNA, protein-protein, or protein-RNA interactions.  MLL 
is part of a large chromatin modifying complex in which the SET domain of MLL has histone 
methyltransferase and histone acetyltransferase activity. During the formation of this complex, MLL 
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protein is proteolytically cleaved into an N- (MLL-N) and a C-terminal (MLL-C) fragment by the protease 
Taspase I. The MLL-N fragment has a Menin binding region, 3 AT hooks, a repression domain, 4 PHD 
fingers, and a CxxC domain. The MLL-C fragment has the transcriptional activation domain, and associates 
with histone acetyltransferases to ensure histone modification and methyltransferase activity. The 
chromosomal break point region is just before PHD.  
 
 
3.1. MLL-rearranged AML is a leukemic stem cell disease 
 
The mixed lineage leukemia is a subtype of leukemia that arises in particular in infants. It 
seems thus likely that the translocation occurs in uterus (Eguchi, 2006). In fact 
environmental factors to which the fetus is exposed in utero may have an important role 
in the development of MLL-rearranged AML, which seem to occur because of 
inappropriate non-homologous end joining of double-strand breaks (Aplan, 2006). 
Normal MLL associates with other factors to activate the transcription of many genes. 
The MLL-N is involved in target selection and is retained in the fusion proteins: for this 
reason it seems that MLL fusions will share many target loci with wild type MLL. This 
assumption has been confirmed for the clustered HOX homeobox genes that are under 
control of MLL as well as of MLL fusion proteins. Remarkably, it has been demonstrated 
that expression of an MLL fusion gene (MLL-AF9) GMPs induces a ‘‘HSC stem cell-like’’ 
signature that includes various HOX genes (Krivtsov, 2006). The acquisition of a stem cell 
signature by leukemic GMPs may contribute to self-renewal of leukemia stem cells. The 
HOX factors, together with their cofactor Meis1, positively regulate the pool size of HSC 
and lineage-specific hematopoietic progenitors by promoting cellular proliferation as 
well as arresting cellular differentiation (Azcoitia, 2005; Lawrence, 2005;  Wang, 2005). 
The dysregulation of Hox genes and Meis1 was directly linked to malignant 
hematopoiesis. In normal hematopoiesis, the expression pattern of the Hox genes and 
Meis1 is dynamic, present at high levels in stem cells and early precursors and quickly 
down regulated as progenitors differentiate (Sauvageau, 1994). Therefore, a continuous 
ectopic HOX expression will block differentiation and create a rapidly proliferating pre-
leukemic precursor pool (Figure 6). There are many other genes regulated by MLL-
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rearrangements, but for certain, HOX deregulation is the most important factor for MLL 
fusion induced leukemogenesis (Milne, 2005;  Zeisig, 2004;  Horton, 2005; Ernst, 2004).  
 
 
 
 
Figure 6: The role of HOX as well as Meis1 proteins in control of hematopoiesis. Transcription factors, as 
Hox genes and Meis1 control hematopoietic differentiation. The expression of these genes must be finely 
downregulated during differentiation. Therefore presence of ectopic factors, such as MLL chimeras,  will 
deregulate expression of these genes causing a block of maturation and promoting a self-renewing of 
precursor cells (figure adapted from (Slany RK, 2009)). 
 
 
There are accumulating evidence that suggest how the cell of origin , in which a genetic 
lesion occurs, can contribute to the emergence of distinct tumor subtype. In particular, 
Armstrong’s group demonstrates that there is a difference in MLL-AF9-mediated 
leukemia, depending if the cells of origin are HSCs or GMPs (Krivtsov, 2013). In particular, 
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they demonstrate how MLL-AF9 transformed HSCs are more aggressive than MLL-AF9 
transformed GMPs. Functionally defined LSCs are immunophenotypically similar, but 
they have differences in gene expression and DNA methylation that are determined by 
the cell of origin. The Gene expression profile resulting from this study show how 
leukemia that originates from HSCs retains enhanced expression of a set of “stem cell 
associated” genes. Therefore, the expression of MLL-AF9 in GMPs activates a stem cell 
associated program, but the expression of MLL-AF9 in HSCs allows maintenance of a 
more extensive stem cell-derived program that influences the LSCs behavior. All these 
findings indicate that many genes involved in self-renewal process in normal HSCs are 
shared in LSCs and allow the maintenance of a stem cell profile in MLL-related leukemia. 
Thus, investigating genes involved in the differentiation block is a fundamental in order 
to understand the basis of the aggressiveness of this disease.  
 
 
4. ZNF521 
 
The Zinc Finger Protein (ZNF521) (also known as early hematopoietic zinc finger protein 
(EHZF); EVI3 or Zfp521 in mouse) is a transcription factor with 30 Krüppel-like zinc finger 
(ZF) domains and contains an N-terminal 12-amino acid motif that interacts with the 
nucleosome remodelling and histone deacetylation (NuRD) complex, which is conserved 
among other ZF transcriptional repressors, including FOG-1, FOG2, BCL11A and SALL 
family members (Bond, 2004; Lin, 2004), Initially, ZNF521 was identified in a comparative 
analysis of the transcriptional profile between human CD34+ hematopoietic progenitors 
and mature peripheral blood leukocytes (Bond HM, 2004).  This analysis has revealed 
that ZNF521 is abundantly expressed in human CD34+ progenitors and then declines 
rapidly during cytokine-driven differentiation (Bond, 2004). However, it has been shown 
that ZNF521 is also widely expressed all along the body including brain, muscle, heart, 
kidney, spleen, lymph nodes, placenta, thymus, fetal liver and bones (Bond, 2004). In 
particular, it is highly expressed in mesenchymal condensations, in prehypertrophic 
chondrocytes in the growth plate as well as in osteoblasts and osteocytes during 
endochondral bone development (Hesse, 2010; Liu TM, 2013). In all these cell types, it 
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appears to control cell differentiation, as well as the function of mature cells by 
modulating the activity of specific transcription factors. Previous studies in 
hematopoietic cells have shown that ZNF521 negatively regulates Early-B Cell Factor 1 
(EBF1) activity via its C-terminal domain, thus influencing B cell differentiation (Mega, 
2011). It has been also shown that ZNF521 through its NuRD interaction suppresses the 
GATA-1 activity during erythropoiesis (Hong, 2005). Being that GATA-1 a master 
regulator of erythroid cell maturation by activating erythroid-specific genes and 
repressing genes associated with the undifferentiated state, the activity of ZNF521 may 
be critical for the differentiation of hematopoietic progenitors.  
Recently studies, have also demonstrated that other transcription factors such as PU.1 
and HOXC13, can synergistically cooperate to regulate ZNF521 expression (Yu, 2016). Yu 
and colleagues demonstrate that transgenic mice over-expressing Hoxc13 and Pu.1 also 
have increased Zfp521 expression in the fetal liver, the site of B-cell differentiation 
during development. 
Thus, in a hematopoietic context these observations lead to speculate that ZNF521 could 
play a critical and specific role in human hematopoiesis. This latter, it is also corroborate 
by the observations that ZNF521 expression is frequently deregulated in hematopoietic 
malignant cells. Early studies have shown that ZNF521 mRNA is highly expressed in 
several AML samples (FAB M2, M3 and M4) as well as CMLs (Bullinger, 2004; Bond, 
2004). Intriguingly, in a study conducted on 363 adult acute leukemia was found that 
MLL rearrangements associate with high levels of ZNF521 (Kohlmann, 2005). Moreover, 
it has been described in a case of B cell-progenitor ALL, a translocation resulting in the 
fusion of PAX5 gene with ZNF521 gene (Mullighan, 2007) and most recently was 
identified ZNF521/Zfp521 as a partner to develop B-lineage ALL positive for both E2A-
PBX1 and E2A-HLF chimeric gene product (Sera, 2016).  
Collectively, these findings demonstrate that a deregulated expression of ZNF521 may 
contribute to leukemic transformation  
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AIM OF THE THESIS 
 
 
MLL-fusion proteins are potent inducers of oncogenic transformation, and their 
expression is considered to be the main oncogenic driving force in approximately 10% of 
AML patients. These oncogenic fusion proteins activate specific set of genes, of which 
the overexpression of hoxa9 and MEIS1 has demonstrated to play a synergistic causative 
role in MLL leukemogenesis. Since that both HOXA9 and MEIS1 play an important role in 
the HSC self-renewal/proliferation, we asked whether others transcriptional regulators 
of HSCs might have relevance in MLL-induced leukemia.  
By gene set enrichment analysis (GSEA) we compared the publically datasets for genes 
normally upregulated in HSCs (CD133+) to our pediatric AML patients. The use of GSEA 
analysis allowed us to identify ZNF521 as a new gene among the well-known genes such 
as HOXA9 and MEIS1 in AML patients carrying MLL rearrangements. ZNF521 encodes for 
a transcription factor that in normal and malignant hematopoiesis has initiate to be 
studied and its misexpression expression have been causally linked to acute leukemia. 
The aim of the present study was to establish whether the identified ZNF521 gene is 
required in MLL leukemogenesis. In order to achieve this, we investigated the role of 
ZNF521 in MLL-rearranged AML, through the study of the knockdown of ZNF521 in a 
series of human MLL-rearranged cell lines and patient-derived xenograft cells. We 
analyzed the contribution of ZNF521 to leukemogenesis by a series of functional and 
mechanistic studies and investigated the ZNF521-dependent molecular pathway using as 
model THP-1 AML cell line. 
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MATHERIALS AND METHODS 
 
 
1. PATIENT SAMPLES AND CELL LINES 
 
All of the pediatric AML patient samples were obtained at the time of diagnosis from the 
University-Hospital of Padua and stratified according to the AIEOP AML 2002/01 protocol 
AML 2002/01 (Pession, 2013). Patient characteristics are listed in Table 1.  
 
 
Non-MLL-rearranged (n = 34)  MLL-rearranged (n = 16) 
normal karyotype  13 
(38%) 
 t(10;11)(MLL-AF10) 5 (31%) 
t(15;17)(PML-RARα) 6 
(18%) 
t(9;11)(MLL-AF9) 5 (31%) 
inv16(CBFB-MYH11) 3 
(9%) 
t(6;11)(MLL-AF6) 3 (19%) 
t(8;21)(AML1-ETO) 8 
(23%) 
11q23 others * 3 (19%) 
FLT3-ITD + 4 
(12%) 
  
 
Table 1: Genotype features of the 50 childhood AML patients analyzed for ZNF521 expression  by qRT-
PCR analysis. 
*t(11;19)(MLL-ENL) n=1; t(11;19)(MLL-ELL) n=1; t(X;11)(MLL-SEPTIN6) n=1 
 
 
 
Seven BM samples from healthy donors were obtained as control. All human myeloid cell 
lines (THP-1, NOMO-1, OCI-AML4, ML2, HL60, K562, Kasumi-1, NB4, U-937, SEM and 
REH) were obtained from DSMZ (Braunschweig, Germany) and 293T cells were obtained 
from ATCC (Manassas, VA, USA). All cell lines were maintained under standard conditions 
suggested by the manufacturer.  
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2. QUANTITATIVE REAL TIME PCR  
 
Total RNA was extracted with Trizol reagent (Invitrogen) and reverse transcribed into 
cDNA using the Superscript III First-Strand Synthesis System (Life Technology). The mRNA 
levels of ZNF521, PU.1, C/EBPα, HOXA9 and MEIS1 were measured by quantitative RT-
PCR (qRT-PCR) with SYBR green on an AB 7900HT real time system (Applied Biosystem) 
using the comparative Ct method and the GAPDH gene expression as internal control 
(Schmittgen, 2008). The primer sequences for quantitative qRT-PCR are listed in Table 2.  
 
 
Sequence of the primers used in this study 
 
Primers for qRT-PCR 
Gene 
name 
Forward 5’ → 3’ Reverse 5’→ 3’ 
GAPDH AGGGCTGCTTTTAACTCTGGT CCCCACTTGATTTTGGAGGGA 
ZNF521 ACTGAAGTTTGGCAGGAGAG TGGGATATTCAGGTTCATGTT 
PU.1 AGAAGACCTGGTGCCCTA CCAGTAATGGTCGTCATGGC 
C/EBPα AACATCGCGGTGCGCAAGAG TTCGCGCTCAGCTGTTCCA 
HOXA9 AAAACAATGCTGAGAATGAGAGC TATAGGGGCACCGCTTTTT 
MEIS1 TGATCAGCAGGCAAAGATTG CATACTCCCTGGCATACTTTG 
 
Primers for ZNF521 promoter^  
Gene 
name 
Forward 5’ → 3’ Reverse 5’→ 3’ 
ZNF521
P1 
AGCTGCTAGCACATTAAACTATACCAAAGA
AATCCA 
AGCTAAGCTTAAAACTATACTCAGTTCCCAGT
TCC 
ZNF521
P2 
AGCTGCTAGCTCCATGTGACGTTCTTAAATG
C 
AGCTGCTAGCTTAGCCACTGCAGAAAGGTAA
A 
ZNF521
P3 
AGCTGCTAGCTGACGTTCTCATTGTAGCTG
GT 
AGCTAAGCTTATGAAGCCAAAGCCATCATC 
ZNF521
P4 
AGCTGCTAGCTCCAGGCAGTTTACAGGTTA
GA 
AGCTGCTAGCCTGTACGTAATCACTGAGGAA
ATCAT 
ZNF521
P3.1 
AGCTGCTAGCTGACGTTCTCATTGTAGCTG
GT 
AGCTAAGCTTATGAAGCCAAAGCCATCATC 
ZNF521
P3.2 
AGCTGCTAGCAAGTTGCTGCATTCTGCTCA AGCTAAGCTTTTTCCTTTCGTGTGGTAGCC 
ZNF521
P3.3 
AGCTGCTAGCTATCACACATAACTTGGGAC
CAC 
AGCTCTCGAGGTGGAAATTAAGAGATTCAGA
ATACG 
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Primers for ChIP analysis 
Gene 
name 
Forward 5’ → 3’ Reverse 5’→ 3’ 
HOXA9 AATGCGATTTGGCTGCTTTTTTATGGC TCAAATCTGGCCTTGCCTCTG 
ZNF521
p3.3 
ACACATAACTTGGGACCACAC GTCTAACCTGTAAACTGCCTGGA 
 
 
shRNA sequences in Mission shRNA pLKO.1-puro-CMV-TurboGFP 
shZNF52
1_9004 
GTACCGGATCACTTGAAGATCCACTTAACTCGAGTTAAGTGGATCTTCAAGTGATTTTTTTG 
shZNF52
1_9710 
CCGGACAAGTTGCAGCAGCATATTTCTCGAGAAATATGCTGCTGCAACTTGTTTTTTG 
shScram GGACAAGTTGCAGCAGCATATTTCTCGAGAAATATGCTGCTGCAACTTGTTTTTT 
 
Table 2: List of Primers used in this study. ^ The restriction enzyme sites are underlined. 
 
 
3. LENTIVIRAL SHRNA VECTOR, TRANSDUCTION AND FACS-SORTING   
 
For knockdown studies, two shRNAs against ZNF521 and a control scrambled shRNA 
(shScram) were used (Mission pLKO.1-puro-CMV-TurboGFP system, Cat Number 
TCRN0000229710 and TCRN0000229004, Sigma-Aldrich) (see Table M2 for shRNA 
sequences). Lentiviral cell transduction was performed as described previously 
(Indraccolo, 2002). After culture in fresh medium and 96 hours after infection, GFP-
positive cells were sorted using a MoFlo XDP cell sorter (Beckman Coulter) and used for 
further experiments. Alternatively, cells were gated for GFP expression and subjected to 
flow cytometry analyses. ZNF521 knockdown efficiency was measured by qRT-PCR and 
western blot analyses.  
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4. PLASMIDS CONSTRUCTS, TRANSIENT TRANSFECTION AND 
LUCIFERASE ASSAY 
 
pMSCV-neo-Flag-MLL-AF9, MSCV-PML-RARA-IRES-GFP, MSCV-AML1-ETO-GFP, 
pCMVMLL-3xFlag and pCMVMLL-ENL-3xFlag have been previously described (Abdul-
Nabi, 2010; Liu, 2007; Tan, 2011). Flag-tagged proteins were previously verified by 
Western blot with anti-Flag M2 antibody (Sigma), as well as the GFP-tagged proteins by 
expression of green fluorescence protein (GFP) in vitro.  
Wild-type ZNF521 promoter from -4493 to + 65 relative to the transcription start site 
(TSS) was divided in four genome fragments [P1 (-3810 to 4993), P2 (-2560 to 3970), P3 (-
1060 to 2729) and P4, +62 to -1260)] and each one was isolated from a genomic DNA 
obtained from a pool of buffy coat by PCR amplification using primer pairs containing 
specific restriction sites. All PCR products were purified, sequenced and cloned in TOPO 
TA cloning kit (Invitrogen). P1 and P3 plasmids were XhoI/HindIII-digested and the 
fragments were recloned into XhoI/HindIII sites downstream of the luciferase gene of the 
pGL42.8 luciferase vector (Promega) to generate ZNF521P1-luc and ZNF521P3-luc 
constructs, respectively. Similarly, P2 and P4 plasmids were NheI/XhoI-digested and the 
fragments inserted into NheI/XhoI sites of pGL42.8 vector to generate ZNF521P2-luc and 
ZNF521P4-luc constructs, respectively. The genome fragment P3 (-1060 to 2729) was 
subdivided in three smaller parts [P3.1 (-2101 to -2729), P3.2 (-1533 to -2143) and P3.3 (-
1060 to -1610)] and each part was PCR amplified from genomic DNA using primers 
containing specific restriction sites and cloned in TOPO TA vector. P3.1 and P3.2 plasmids 
were XhoI/HindIII-digested and the fragments were recloned into XhoI/HindIII sites of 
pGL42.8 vector to generate ZNF521P3.1-luc and ZNF521P3.2-luc constructs. P3.3 plasmid 
was NheI/XhoI-digested and the fragment recloned into NheI/XhoI-digested pGL42.8 to 
generate ZNF521P3.3 construct. (Primers used for genomic DNA amplification are listed 
in Table M2).  
For luciferase assay, 293T cells were cotransfected with 0.5 µg of the reporter plasmid, 1 
µg of expression plasmid or empty vector and 0.5 µg of Renilla luciferase reporter vector 
(Promega) as internal control for normalization of transfection efficiency, for a total of 2 
µg of combined plasmids per well. The cells were then harvested at 48 hours after 
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transfection using a Dual-Luciferase reporter assay system (Promega) and the Victor3 TM 
1420 Multilabel Counter (PerkinElmer). Data are presented as the mean ratio for 
triplicate experiments. 
 
 
5. CHROMATIN IMMUNOPRECIPITATION (CHIP) AND PCR DETECTION 
 
ChIP assay was performed using the Imprint Chromatin Immunoprecipitation kit (Sigma), 
according to the manufacturer's protocol with minor modifications. Briefly, 293T cells 
(3.5 × 106 cells) were transfected with 10 µg of Flag-MLL-AF9 or Flag-MLL-ENL expression 
plasmids. 48 hours post transfection, were cross-linked with 1% formaldehyde (Sigma) 
for 15 minute at room temperature. Subsequently, the lysed cells were isolated and 
sonicated on ice to shear DNA into fragments of 200 bp to 1 kb. Then, the chromatin 
complexes were incubated into pre-treated Stripwells (Sigma) with anti-Flag M2 
monoclonal antibody (Sigma), or normal mouse IgG (Sigma) as indicated. The input DNA 
was isolated from sonicated lysates before immunoprecipitation as a positive control. 
Purified DNA was then resuspended in TE buffer (10 mM Tris-HCL and 1 mM EDTA, pH 
8.0) for PCR. ChIP assay from 2 x106 of MLL-AF9-expressing NOMO-1 cells or HL60 cells 
was performed as above reported using a N-terminal MLL monoclonal antibody (Santa 
Cruz Biotechnology) or a C-terminal MLL polyclonal antibody (Sigma) or a mouse IgG 
(Sigma) as indicated. Purified ChIP DNA was amplified by regular PCR. Primers amplifying 
the ZNF521 promoter region and the HOXA9 promoter region used for the ChIP PCR are 
listed in Table 2.   
 
 
6. MICROARRAY ANALYSIS 
 
Total RNA from sorted THP-1 cells transduced with shRNAs was isolated using Trizol as 
above reported and processed for microarray analysis using the Affymetrix GeneChip 
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3’IVT express Kit (Affimetrix) after RNA quality control using Agilent 2100 Bioanalyzer 
(Agilent). Gene expression profile was performed using a Human Genome U133 2.0 Plus 
chip (Affymetrix), as previously described (Bresolin, 2010). The data were RMA-
normalized using R software (http://www.r-project.org/) with BioConductor package 
(www.bioconductor.org). Shrinkage t test was used to identify differentially expressed 
genes between shScram and shRNA ZNF521 THP-1 cells selected with a local FDR <0.05 
(FDR). Hierarchical clustering analyses were performed using Euclidian distance and 
Ward’s methods. Gene set enrichment analysis (GSEA) was performed using GSEA 
version 2.0 software (Broad Institute; http://www.broadinstitute.org/gsea) with genes 
ranked by difference of class and statistical significance by 1000 gene set permutations. 
Gene set permutation was used to enable direct comparisons between shScram and 
shRNA ZNF521 results (<7 replicates). Median of probes was used to collapse multiple 
probe sets to a single value per gene for each sample. Gene sets with a FDR <0.05 were 
declared to be statistically significant. The microarray gene expression data have been 
submitted in NCBI’s Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) 
under accession GSE79110 
 
 
7. WESTERN BLOT AND IMMUNOFLUORESCENCE STAINING 
 
Western blot and immunofluorescence were performed using standard procedures. The 
antibody against ZNF521 was from Novus Biologicals (72009). Gamma-Tubulin (T6557), 
Actin (A5316), Flag M2 (F3165) antibodies were from Sigma Aldrich. For 
immunofluorescence analysis, antibody against CDKN1A/p21 (2947S) was from Cell 
Signaling and antibody against CDKN1B/p27 (610241) was from BD Biosciences.  
For immunofluorescence analysis, 5 × 104 FACS-sorted cells were harvested 7 days after 
transduction and cytocentrifuged onto slides at 500 rpm for 5 minutes (Cytospin 4 
cytocentrifuge, Thermo Scientific). Cells were fixed in 4% formaldehyde for 15 minutes, 
permeabilized with PBS containing 0.1% Triton X-100 (Sigma) for 10 minutes, and 
blocked with 5% BSA in PBS for 30 minutes at room temperature, followed by incubation 
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with primary antibodies in 1% BSA-PBS overnight at 4°C. The following day, slides were 
washed with PBS and incubated with the secondary antibody Alexa Fluor 594 Goat Anti-
mouse IgG (H+L) (1:2000, Life Technologies) for 1 hour at room temperature. Nuclei 
were stained with 4′,6-diamidino-2-phenylindole (DAPI, 1:10000; Sigma) for 13 minutes. 
A minimum of 50 cells/sample was scored in three different fields in at least three 
independent cytospin preparations. Cells were visualized and counted by a confocal 
microscope (Vico, Eclipse Ti80, Nikon) equipped with a digital camera. Images were 
captured with ImageProPlus software (Media Cybernetics). 
 
 
8. CELL FUNCTION ANALYSIS  
 
8.1 Cell viability and clonogenic assay  
 
Viability assay was performed using the colormetric diphenyltetrazolium bromide (MTT) 
Cell Proliferation Kit I (Sigma) and measured via Victor 3 Microplate reader 
(PerkinElmer). Briefly, FACS-sorted GFP positive cells (5 × 104) from cell lines and/or ex 
vivo primary patient-derived cells were collected 4 days after transduction and seeded 
(in triplicates) in 96-well culture plate. At a designated time point, cell viability was 
measured by adding 10 µl of MTT solution (5 mg/ml) to each well. After 3 hours of 
incubation, the absorbance (OD) of each well was measured at 570 nm using a 
microplate reader (Victor 3; PerkinElmer). Cell proliferation was calculated by the 
following formula: (mean OD ZNF521-shRNA wells)/(mean OD shScram-control wells) × 
100%. For the clonogenic assay, 2 × 103 cells at day 4 of transduction were FACS-sorted 
and then resuspended and seeded in methylcellulose medium (MethoCult H4534; Stem 
Cell Technologies). After 14 days, colonies were counted under 20x magnification with a 
stereoscope after exposure to MTT (Sigma) for 3 hours at 37° C. 
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8.2. Cell cycle, apoptosis assay  
 
Cell-cycle analysis was performed by flow cytometric analysis of propidium iodide-
stained cells at 7 days after shRNA transduction. Briefly, 2.5 × 105 cells were washed in 
PBS and then fixed in 70% ethanol and put at -20°C overnight. The samples were 
rehydrated in cold PBS, treated with lysis buffer containing RNase and 0.1% Triton X-100 
(Sigma) and stained with propidium iodide (PI). Cell cycle distribution was measured on 
gated GFP-positive cells. Analyses were performed using the Cytomics FC500 flow 
cytometer (Beckman Coulter, Brea, CA) and MultiCycle Cell Cycle Analysis Software 
(Phoenix Flow Systems, San Diego, CA). A minimum total of 10.000 gated events were 
collected for each sample. Cell death was measured at day 4 and day 7 after transduction 
using AnnexinV-Fluos staining kit (Invitrogen) and analyzed by flow cytometry. Briefly, 
2.5 × 105 cells were resuspended in 100 µl of 1x annexinV-binding buffer and incubated 
with 1 µl of allophycocyanin-conjugated annexinV (Invitrogen) and 1 µl of DAPI (1:10000, 
Sigma) for 15 minutes at room temperature. The apoptotic cells (AnnexinV+/DAPI-) were 
determined on gated GFP-positive cells as described above.  
 
 
8.3. Expression of CD11b and CD14, morphological analysis and cell 
differentiation induction  
 
PE-conjugated anti-CD11b (BD Biosciences) and Phycoerythrin-Cyanin (PC7) anti-CD14 
(Beckman Coulter) were used to analyze myeloid differentiation. Briefly, on day 7, 2 × 
105 transduced cells were harvested, washed and labeled with conjugated antibodies in 
PBS for 15 minutes in the dark. Then, cells were washed and analyzed by flow cytometry 
of gated GFP-expressing cells as previously reported. The expression of the cell surface 
markers was analyzed with a Cytomics FC500 flow cytometer (Beckman Coulter, Brea, 
CA). Cell morphology was determined on cytospin preparations. Four days after 
transduction, GFP positive cells were FACS-sorted and placed in culture. Three days later 
(7 days post-transduction), 0.5 × 105 cells were harvested and washed in PBS buffer and 
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spun onto slides for 5 minutes at 500 rpm using a Shandon CytoSpin4 cytocentrifuge and 
the slides were stained with a Wright-Giemsa stain. Images were taken at 40x 
magnification using a Nikon microscope (Vico, Eclipse Ti80, Nikon) and acquired with 
ImageProPlus software (Media Cybernetics). For the differentiation induction with ATRA 
(1µM; Sigma) or Securinine (15 µM; Sigma), after 3 days of treatment cells were 
collected and analyzed for cell morphology, level of ZNF521 transcripts and protein 
expression as previously described. 
 
 
9. STUDIES WITH AML PATIENT-DERIVED XENOGRAFT CELLS  
 
Primary MLL-AF9-expressing cells were obtained from BM samples of diagnosed AML 
pediatric patients stored in the BioBank of the laboratory of Pediatric Hematology of the 
University Hospital of Padua, (Italy) according to the guidelines of the local ethics 
committee. Initial AML xenografts were established by tail vein injection with 8 × 106 
primary cells suspended in 300 μl of PBS in 6- to 8-week-old NSG mice, which were 
purchased from Charles River (Wilmington, MA, USA). All animal experiments were 
performed in accordance with institutional guidelines and established protocols 
(Agnusdei, 2014). Engraftment was monitored by weekly blood collections and flow 
cytometry analysis with antihuman CD45 (BD Biosciences). The engraftment rate was 
defined by the number of days required for the transplanted human CD45+ cells to reach 
at least 20% in the peripheral blood. Human leukemic cells from the spleens of engrafted 
mice were collected and cultivated in RPMI supplemented with 10% Human serum 
(Euroclone), antibiotics, and cytokines SCF, FLT-3L and TPO (40 ng/ml for each), IL-3 and 
IL-6 (20 ng/ml for each). (All cytokines were obtained from Inalco, Milan, Italy). For ex 
vivo experiments, two independent biological replicates were performed. 
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10. DATA ANALYSIS 
 
Data are presented as mean ± SD. Each experiment was performed at least 3 times, 
except where stated otherwise. The differences were examined using 2-tailed t test, 
Mann–Whitney U-test or kruskal-Wallis one-way analysis of variance followed Dunn’s 
test as appropriate (GraphPad Prism; GraphPad). Results were considered significant at 
P<0.05. 
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RESULTS 
 
 
1. GSEA analysis of upregulated stemness genes in pediatric AML 
 
One of the most important features of AML carrying MLL rearrangements is that to show 
an up-regulation of stem cell-associated genes including HOXA and MEIS1. In order to 
identify other uncharacterized stemness genes, we interrogated public signatures based 
on CD133+ cell populations isolated from normal/healthy versus gene expression profiles 
of 82 pediatric AML samples (61 with normal MLL and 21 with MLL rearrangements) 
previously analyzed. As shown in Figure X, among the canonical upregulated genes, 
whose overexpression are hallmarks of MLL-rearranged AML, we observed the ZNF521 
gene. Interestingly, ZNF521, which encodes a transcription factor, is a marker of HSC 
(Matsubara, 2009) with potential role in the regulation of HSC homeostasis, but with 
unknown function in MLL-mediated leukemogenesis. 
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Figure 7. Gene Set Enrichment Analysis (GSEA). Heat map displaying the Jaatinen hematopoietic stem 
cell_upregulated gene in CD133+ versus CD133- normal cells in 82 AML pediatric samples including 21 
MLL-rearranged. among the top five most differentially expressed genes (red box), ZNF521 appears among 
the genes most upregulated in aml samples with MLL rearrangements (gray lanes) than AML sample 
without MLL rearrangements (yellow lanes). 
 
 
2. ZNF521 IS ABERRANTLY OVEREXPRESSED IN PEDIATRIC MLL-
REARRANGED AML  
 
Previously, by use of microarray analysis, we found a frequent ZNF521 overexpression in 
pediatric AML with MLL rearrangements (Pigazzi, 2011). To validate these data and 
analyze the relationship between ZNF521 expression and distinct MLL-fusion genes, we 
performed quantitative real-time PCR (qRT-PCR) in an independent cohort of 50 pediatric 
AML patients (16 MLL-rearranged and 34 non-MLL-rearranged; Table 1) and 7 normal 
bone marrow (BM) controls. We found that ZNF521 was expressed at significantly higher 
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level in AML patients with MLL rearrangements compared to non-rearranged AML and 
normal controls (P<0.001, Figure 8). 
 
 
Figure
 
 
Figure 8. ZNF521 is aberrantly overexpressed in MLL-rearranged AML. (A) qRT-PCR for the expression of 
ZNF521 in 16 MLL-rearranged AML (MLL), 34 non-MLL-rearranged AML (Non-MLL) and 7 normal control 
(NC). The results are normalized to GAPDH and analyzed by 2−ΔCt method. NS, not significant, **P<0.001, 
kruskal-Wallis test. (B) qRT-PCR analysis of ZNF521 expression in a representative panel of   human 
leukemic cell lines normalized to GAPDH and analyzed by 2−ΔCt method. Data are represented as mean ± 
SD of three independent experiments. y axis is linear. Inset, dot plots of mean ZNF521 mRNA levels in 
MLL15 rearranged and non-MLL-rearranged cell lines from data presented in (B). *P<0.05, Mann–Whitney 
U-test. 
 
 
The analysis of ZNF521 expression between the most frequent MLL rearrangements 
detected in pediatric AML did not reveal significant difference based on MLL fusion 
partners (data not shown). In addition, we analyzed the expression of ZNF521 in 6 MLL-
rearranged and 6 non-MLL-rearranged human leukemic cell lines. Similarly, leukemic cell 
lines with MLL rearrangements, with the exception of those carrying MLL-AF4 fusion 
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transcripts, showed significantly higher ZNF521 mRNA levels compared to cell lines with 
other abnormalities (P<0.05, Figure RB). Thus, our data indicate that ZNF521 is likely 
involved in MLL-mediated transformation in AML.   
 
 
3. ZNF521 DEPLETION REDUCES CELL VIABILITY AND CAUSES CELL 
CYCLE ARREST WITHOUT INDUCING APOPTOSIS OF MLL-REARRANGED 
AML CELL LINES.  
 
To determine whether ZNF521 is functionally important in MLL-rearranged AML, we first 
examined the effects of ZNF521 knockdown on the cell proliferation using a panel of 
human MLL-rearranged AML cell lines, including, THP-1, NOMO-1 (both expressing MLL-
AF9), ML-2 (expressing MLL-AF6) and OCI-AML4 (expressing MLL-ENL). To suppress 
ZNF521, we used GFP-tagged lentiviral vectors expressing anti-ZNF521 shRNAs (ZNF004 
and ZNF710) or a non-targeting shRNA sequence (shScram). After assessing transduction 
efficiency by flow cytometry (range 30-80%) (Figure 9 and data not shown), GFP-positive 
cells were sorted and maintained under standard cell culture conditions for subsequent 
analysis. 
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Figure 9. Flow cytometry analysis and gating strategy of shRNA transduced human MLL-rearranged AML 
cell lines. Transduced cell lines were GFP-sorted at day 4 and analyzed or maintained in culture for further 
evaluation. Otherwise transduced cells were analyzed after being gated for the GFP+ cells. Representative 
flow cytometry dot plots of gated GFP+ cells after transduction with GFP lentiviral expressing shRNA 
against ZNF521 (ZNF004 and ZNF710) or expressing non-targeting shRNA sequence (shScram) are 
presented. The selected area indicates the sorting gates and includes the percentage of cells in each 
sorting gate. Gates were set to collect GFP high and GFP low-expressing cells. SSC, side scatter. 
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As expected, in all four cell lines downregulation of ZNF521 varied between 60% and 75% 
compared to ZNF521 mRNA expression in shScram-transduced cells, and this correlated 
with a decrease in ZNF521 protein amount (Figure 10).  
 
 
 
Figure 10. shRNA-mediated knockdown of ZNF521 in MLL-rearranged AML cell lines. (A) ZNF521 mRNA 
levels evaluated by qRT-PCR on GFP+ sorted cells after 4 days of transduction with shScram and ZNF521 
shRNAs (ZNF004 and ZNF710). The results are relative to shScram-transduced cells, normalized to GAPDH 
and analyzed by 2
−ΔΔCt
 method. Data are represented as mean ± SD of three independent experiments. (B) 
Western blot analysis for ZNF521 of cells used in (A). ϒ-tubulin was used as loading control. 
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In addition, ZNF521 knockdown progressively reduced viability of all the transduced cell 
lines (Figure 11A), and it inhibited colony formation ability of MLL-rearranged cells, 
measured 2 weeks after transduction (Figure 11B). In order to get a deeper insight, cell 
cycle analysis and apoptosis induction were assessed in GFP-positive MLL-rearranged 
cells. At day 7, we observed an accumulation of cells in G1 phase (17%-77%) in three out 
of four cell lines (THP-1, NOMO-1 and ML-2) expressing anti-ZNF521 shRNAs. This was 
most likely due to S phase reduction (from 29% to 65%) rather than G2/M alterations 
(Figure 11C). However, annexin V/DAPI assay measured at day 4 and day 7 demonstrated 
that ZNF521 knockdown did not caused increased apoptosis (Figure 11D), suggesting 
that ZNF521 may be involved in proliferation and differentiation of MLL-rearranged cells 
rather than in cell survival.  
 
 
 
FIGURE 11: ZNF521 depletion impairs cell proliferation, induces cell cycle arrest but not apoptosis in 
MLL-rearranged cell lines. 
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(A) MTT cell viability assay in the MLL leukemic cells THP-1, NOMO-1, OCI-AML4 and ML2 transduced with 
ZNF521 shRNAs (ZNF004 or ZNF710) or non-targeting scramble control (shScram). GFP+ cells were sorted 4 
days after transduction and placed in appropriate medium. Graphs show percentage of GFP+ cells 
measured at day 4, day 7 and day 10, normalized to the percentage of shScram cells. Data are represented 
as mean ± SD of at least three independent experiments. *P<0.05, **P<0.001, ***P<0.0001, t-test. (B) 
Colony formation of GFP+ cells transduced with ZNF521 shRNAs or shScram. Error bars represent mean ± 
S.D. of three independent experiments. **P<0.001, ***P<0.0001, t-test. (C) Cell cycle distribution at day 7 
of ZNF521 knockdown cells and control shScram of gated GFP+ cells. Data are represented as mean ± SD of 
three independent experiments. **P<0.001, ***P<0.0001, t-test. (D) Percentage of apoptotic cells 
(Annexin V+/DAPI- and Annexin V+/DAPI+) measured after 4 and 7 days post-transduction of gated GFP+ 
cell population. Data are represented as mean ± SD of three independent experiments.   
 
 
To substantiate this hypothesis, GFP-sorted transduced THP-1 and ML-2 cells were 
collected on glass slides by cytospin and stained with antibodies against p21 (CDKN1A) 
and p27 (CDKN1B) cell cycle inhibitors (Roy, 2015). At day 7, we observed an increase of 
both p21 and p27 protein expression in ZNF521 knockdown cells, suggesting a prolonged 
G1/S transition as the main reason for the aforementioned cell cycle arrest (Figure 12). 
Taken together, these findings indicate that ZNF521 expression is essential in the growth 
potential of MLL-rearranged AML cell lines. 
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Figure 12. ZNF521 depletion increases the expression signal of p21 and p27. (A) Representative confocal 
imaging on cytospin preparations of THP-1 and ML-2 cell lines analyzed for p21 and p27 expression by 
immunofluorescence assay. Transduced cells with shScram or ZNF521 shRNAs (ZNF004 or ZNF710) at day 7 
were stained with anti-p21 and anti-p27 antibodies and Alexa Fluor 594-conjugated goat anti-mouse IgG 
(red). Corresponding nuclei were counterstained with DAPI (blue). Original magnification, x 40. Images 
were collected by confocal microscope (Vico, Eclipse Ti80, Nikon) and processed with ImageProPlus 
software (Media Cybernetics). Results are representative of at least three independent experiments for 
each cell line. (B) Percentage of p21 and p27 positive cells was quantified respect to total nuclei (see 
supplemental method). Data are mean ± SD of three cytospin preparations for each cell line of three 
independent experiments. * P<0.05, t-test 
 
 
4. DEPLETION OF ZNF521 INDUCES MYELOID DIFFERENTIATION OF 
MLL-REARRANGED AML CELL LINES. 
 
Given that ZNF521 can regulate lineage progression of different cell types, including 
hematopoietic cells (Bond, 2004; Matsubara, 2009; Mega, 2011), we analyzed whether 
ZNF521 depletion might influence differentiation in MLL-rearranged leukemic cells. Flow 
cytometry analysis of CD11b and CD14 myeloid markers was then performed on GFP-
positive cells and revealed a change of these markers in 3 out of 4 cell lines transduced 
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with ZNF521 shRNAs (Figure 13A). The phenotypic changes were also sustained by a 
more mature macrophage-like morphology observed in all these cell lines upon ZNF521 
depletion as compared with transduced control cells (Figure 13B). Additionally, 
maturation induced by ZNF521 depletion was also supported by upregulation of C/EBPA 
and PU.1 mRNA levels, two myeloid differentiation markers (Figure 13C). 
 
 
Figure 13. ZNF521 depletion induces myelomonocytic differentiation in MLL-rearranged cell lines.  
(A) Representative flow cytometry dot plots of gated GFP+ cells analyzed for CD11b and CD14 expression 
after 7 days of transduction. The mean percentage of CD11b+/CD14-, CD11b-/CD14+, CD11b+/CD14+ and 
CD11b-/CD14- cells of three biological replicates are shown below. (B) Representative Wright-Giemsa 
staining of cytospin preparations at day 7 of THP-1, NOMO-1, OCI-AML4 and ML2 GFP+ cells transduced 
with ZNF521 shRNAs or shScram. Original magnification, x 40. (C) qRT-PCR on THP-1 GFP+ cells for the 
expression of ZNF521, PU.1 and C/EBPα at day 7 post transduction with ZNF521 shRNAs or shScram. The 
results are relative to shScram-transduced cells, normalized to GAPDH and analyzed by 2
−ΔΔCt
 method. Data 
are represented as mean ± SD of three independent experiments. ** P<0.01, t-test. 
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Furthermore, a downregulation of ZNF521 expression occurred in response to treatment 
with all-trans retinoid acid (ATRA) and with Securinine, two differentiation agents 
administered to THP-1 and NOMO-1 AML cells, respectively (Figure 14).  
 
 
 
Figure 14. Effect of differentiation-induced agents on ZNF521 expression in human MLL-rearranged cell 
lines. (A) qRT-PCR (left panel) and Western blot (middle panel) analyses of ZNF521 in THP-1 cell line after 
treatment with 1µM ATRA for 72 hours compared with vehicle control (0.1% DMSO). For qRT-PCR data the 
ZNF521 mRNA expression is shown relative to vehicle control normalized to GAPDH and analyzed by 2
−ΔΔCt
 
method. Data are represented as mean ± SD of three independent experiments. *** P<0.001, t-test. 
Representative Wright-Giemsa-stained cytospin preparations of cells treated with 1µM ATRA for 72 hours 
(right panel). Original magnification, x 60. (B) Same experiments as in (A) were performed in NOMO-1 cell 
line after 72 hours of treatment with 15µM Securinine. qRT-PCR (left panel), Western blot (middle panel) 
analyses of ZNF521 expression and representative Wright-Giemsa-stained cytospin preparations of NOMO-
1 cell lines after 72 hours of treatment (right panel) are shown.  
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In particular, ATRA and Securinine, previously tested on these cell lines by others (Niitsu, 
2001; Gupta, 2011), were able to reduce ZNF521 mRNA and protein expression, and 
stimulate MLL-rearranged cell differentiation, supporting the hypothesis that ZNF521 is 
required to maintain those cells in an undifferentiated state.  
 
 
5. EFFECTS OF ZNF521 DEPLETION IN PATIENT-DERIVED AML 
XENOGRAFT CELLS. 
 
To extend our findings to primary cells containing MLL-AF9 oncogene, we transduced 
ZNF521 shRNAs in ex vivo cells obtained from patient-derived xenografts (Figure 15A). 
Two out of four patients harboring MLL-AF9 fusion protein (Table 4) resulted in 
successful engraftment into NSG mice.  
 
ID WBC,x10
9
/L FAB % BM 
blasts at 
diagnosis 
Disease 
status at 
biopsy 
karyotype 
1426 37.5 NA 90 Diagnosis 46,XY,t(9;11)(p22;q23) 
726* NA M5 80 Diagnosis 46,XY,t(9;11)(p22;q23) 
1315* 85.2 NA 80 Secondary 46,XY,7p,t(9;11)(p22;q23) 
1368 222.4 NA 80 Diagnosis 46,XY,t(9;11)(p22;q23) 
 
Table 4. Clinical features of patients for xenotransplantation into NOD/SCID mice.  
* Sample-patient successfully engrafted; NA not available. 
 
The kinetics of such engraftment, measured by percentage of human CD45+ cells in the 
peripheral blood varying between 22.3% to 42.2%, ranged from 47 to 67 days and led to 
expansion of leukemic cells with the same immunophenotype and cytogenetic features 
of the original patient sample (data not shown). Ex vivo experiments demonstrated that 
ZNF521 depletion strongly impaired viability and colony formation of mononuclear cells 
obtained from two primary MLL-AF9 AML patient-derived xenografts (Figure 15B,C). 
Most importantly, an increased expression of myeloid differentiation markers CD11b and 
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CD14 (Figure 15D) and morphological features of mature monocytes/macrophage blast-
like was observed (Figure 15E). These findings suggest that ZNF521 overexpression is 
critical to maintain an immature phenotype consistent with the MLL-rearranged cell lines 
results. 
 
 
 
 
Figure 15. ZNF521 depletion impairs cell growth and induces differentiation on primary MLL-AF9 AML 
patient-derived xenograft cells. (A) Flow chart of experimental procedure for analyzing the role of ZNF521 
in ex vivo cells obtained from patient-derived xenografts. Leukemic cells from patient #726 or patient 
#1315 were isolated from primary AML mice and infected with lentivirus encoding an shRNA to ZNF521 or 
shScram. Four days after transduction cells were FACS-sorted for GFP expression and cultured. (B) MTT cell 
viability assay in ex vivo cells. Data are represented as mean ± SD of three independent experiments. 
**P<0.001, t-test. (C) Clonogenic growth of transduced ex vivo GFP+ cells following 14 days in 
methylcellulose culture. Data are shown as the means ± SD for triplicate analyses. *P<0.05, **P<0.001, t-
test. (D) Representative flow cytometry dot plots showing expression of CD11b and CD14 in human CD45+ 
cells in the GFP+ cells population. Numbers indicate percentage of the four populations. The mean 
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percentage of CD11b+/CD14-, CD11b-/CD14+, CD11b+/CD14+ and CD11b-/CD14- populations of three 
biological replicates are shown in the right panel. (E) Representative Wright-Giemsa-stained cytospins of ex 
vivo GFP+ cells at day 4 post transduction with ZNF521 shRNA (ZNF004) or shScram. Original magnification, 
x 40.  
 
 
6. GENE EXPRESSION CHANGES AFTER ZNF521 DEPLETION IN THP-1 
CELLS. 
 
To investigate the gene expression pattern in MLL-AF9 AML cells expressing high levels of 
ZNF521, we performed microarray analysis of shZNF521- or shScram-transduced THP-1 
cells. Since that the differentiation was overt after 7 days of transduction as reported 
above, we performed gene expression profiling at day 4 after transduction. A total of 158 
genes showed a significant change of expression (>1.5-fold change, FDR<0.05), 58 were 
upregulated while 100 were downregulated (Figure 16A and Table 5).  
 
 
Probe set 
 
Gene 
Symbol 
 
IFDR 
 
Means_shZNF004 
 
Means_shScram 
 
1555340_x_at RAP1A 7.29E-14 3.272817153 11.69366146 
1555339_at RAP1A 7.29E-14 3.331697417 11.72192487 
203032_s_at FH 7.29E-14 2.593654642 7.004073844 
230659_at NA 7.29E-14 3.364707971 9.071419646 
209811_at CASP2 7.29E-14 3.498066564 6.977897606 
1555830_s_at ESYT2 7.29E-14 3.157621165 6.233288774 
228854_at NA 7.29E-14 4.507943084 8.700411129 
1554451_s_at DNAJC14 7.29E-14 3.443528107 6.599509088 
222611_s_at PSPC1 7.29E-14 3.892862189 6.940868082 
216125_s_at RANBP9 7.29E-14 4.214434937 6.786602432 
227762_at NA 7.29E-14 4.760415465 7.656360326 
242900_at NA 7.29E-14 3.972371741 6.289884015 
210465_s_at SNAPC3 7.29E-14 5.260781091 8.320937398 
209052_s_at WHSC1 7.29E-14 4.011707509 6.321660403 
224577_at ERGIC1 7.29E-14 5.026229524 7.551517562 
219209_at IFIH1 7.29E-14 9.661284664 6.360666226 
227834_at TXLNB 7.29E-14 5.734833216 3.702313322 
219243_at GIMAP4 7.29E-14 5.377588503 3.461148283 
216598_s_at CCL2 7.29E-14 8.428115374 5.381391593 
203596_s_at IFIT5 7.29E-14 7.756051699 4.938882008 
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227265_at FGL2 7.29E-14 6.933841791 4.350212792 
210889_s_at FCGR2B 7.29E-14 9.3858295 5.882368351 
223551_at PKIB 7.29E-14 9.164302426 5.661218939 
204475_at MMP1 7.29E-14 7.330288469 4.387222797 
229450_at IFIT3 7.29E-14 11.66175734 6.924802655 
206488_s_at CD36 7.29E-14 8.995345742 5.33583655 
228766_at CD36 7.29E-14 7.475487386 4.405886495 
205686_s_at CD86 7.29E-14 5.675449214 3.327806002 
210895_s_at CD86 7.29E-14 7.799936929 4.402895353 
202973_x_at FAM13A 7.29E-14 7.555883194 4.23511804 
231120_x_at PKIB 7.29E-14 6.821698244 3.738890628 
204972_at OAS2 7.29E-14 7.437693218 3.962123467 
209555_s_at CD36 7.29E-14 7.849275842 4.152806423 
206584_at LY96 7.29E-14 7.396080064 3.888310801 
226757_at IFIT2 7.29E-14 10.04575707 5.214422189 
206637_at P2RY14 7.29E-14 6.443625151 3.174919145 
212956_at TBC1D9 7.29E-14 8.199774221 3.989995117 
227609_at EPSTI1 7.29E-14 10.61497537 4.856721475 
202086_at MX1 7.29E-14 11.59476291 5.268245207 
203153_at IFIT1 7.29E-14 10.51899342 4.701311253 
235276_at EPSTI1 7.29E-14 8.531841866 3.790497541 
214453_s_at IFI44 7.29E-14 10.18360475 4.365661325 
204439_at IFI44L 7.29E-14 9.343279892 2.623412862 
208450_at LGALS2 2.72E-12 6.376452482 4.13836002 
230520_at AIG1 3.62E-12 5.421414771 8.42334648 
225237_s_at MSI2 3.62E-12 4.302027085 6.63526392 
209875_s_at SPP1 3.62E-12 8.939636755 5.245139693 
239512_at SRSF4 5.43E-12 3.424633107 6.122115045 
215099_s_at RXRB 5.43E-12 3.360896669 5.182917746 
214022_s_at IFITM1 1.09E-11 9.639456366 5.780716705 
227242_s_at EBF3 1.40E-11 3.198777829 6.501337123 
209160_at AKR1C3 1.40E-11 6.237174611 3.467544531 
209409_at GRB10 1.52E-11 5.53032405 8.592046019 
226841_at MPEG1 1.52E-11 5.439137025 3.463256631 
206291_at NTS 8.04E-11 5.202834617 3.37912861 
235625_at VPS41 1.12E-10 4.019442688 6.888053529 
219352_at HERC6 1.12E-10 8.512887407 5.127299556 
242625_at RSAD2 1.12E-10 7.759363805 3.535304072 
227260_at NA 1.68E-10 3.468106472 5.812574528 
229128_s_at ANP32E 1.92E-10 3.065627289 8.041154478 
211825_s_at FLI1 2.56E-10 4.505153042 7.70808605 
204273_at EDNRB 1.21E-09 4.644985144 3.081504207 
220059_at STAP1 1.21E-09 6.948836147 3.9587154 
34449_at CASP2 2.22E-09 3.371752104 5.343900903 
202869_at OAS1 2.40E-09 8.708784226 3.999158316 
209925_at OCLN 2.53E-09 3.66215453 5.709879327 
213562_s_at SQLE 2.70E-09 3.41534405 6.727026189 
219895_at TMEM255A 3.97E-09 5.912972966 2.952282219 
212681_at EPB41L3 6.35E-09 6.875338979 4.226037005 
1552658_a_at NAV3 2.21E-08 4.719195295 7.76328231 
210139_s_at PMP22 2.21E-08 6.202295096 3.699815143 
229167_at PURA 4.17E-08 4.433892969 6.889873925 
217403_s_at ZNF227 5.67E-08 3.767873968 6.526712195 
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211559_s_at CCNG2 6.59E-08 4.422448321 8.428323945 
219196_at SCG3 6.59E-08 5.429712116 2.812053741 
213872_at NA 1.09E-07 3.010296172 7.791453316 
201693_s_at EGR1 1.09E-07 4.539918709 7.633098497 
210875_s_at ZEB1 1.09E-07 2.896438208 4.421607261 
222614_at RWDD2B 1.98E-07 3.450423478 5.86072941 
1553117_a_at STK38 2.10E-07 3.665817621 6.939115251 
244774_at PHACTR2 2.10E-07 3.853094162 6.851288289 
233292_s_at NA 3.41E-07 3.184355172 4.827088859 
214539_at SERPINB10 4.15E-07 4.10912414 7.005074609 
224046_s_at PDE7A 6.57E-07 3.65311398 6.146994073 
227803_at ENPP5 6.57E-07 4.717081416 3.098961165 
216917_s_at SYCP1 6.57E-07 5.727581378 3.442402712 
209723_at SERPINB9 6.57E-07 6.525317888 3.87000973 
206336_at CXCL6 6.57E-07 5.61551641 3.22831843 
1554614_a_at PTBP2 9.72E-07 2.851477818 6.01832904 
211450_s_at MSH6 9.72E-07 3.945522181 7.983327736 
1558028_x_at LINC00657 9.72E-07 3.881579348 6.677504769 
205408_at MLLT10 9.72E-07 4.396444854 7.251866597 
243835_at ZDHHC21 1.29E-06 3.131394065 4.933095838 
212009_s_at STIP1 1.29E-06 4.231623821 6.593862637 
235287_at CDK6 2.42E-06 2.962197505 5.106066397 
226134_s_at MSI2 2.42E-06 4.910426996 7.85923352 
242691_at NA 3.29E-06 3.255871284 5.303849989 
225864_at FAM84B 3.29E-06 3.477901748 5.450077376 
223220_s_at PARP9 3.29E-06 10.1340089 6.754157491 
205139_s_at UST 3.29E-06 6.260118791 4.052990312 
205997_at ADAM28 3.29E-06 6.747742756 4.12818658 
207723_s_at KLRC3 3.29E-06 6.848721055 3.928225706 
222863_at ZBTB10 5.30E-06 3.003991336 4.715064116 
228834_at TOB1 6.78E-06 3.10919356 6.508586179 
237346_at TGDS 6.78E-06 2.659434222 4.423719391 
239245_at NA 7.78E-06 2.830149135 4.556059038 
234023_s_at CENPJ 8.03E-06 2.838765479 5.393589327 
213470_s_at HNRNPH1 8.03E-06 4.388092403 7.884930732 
228746_s_at NA 1.37E-05 3.420014404 7.3567208 
222719_s_at PDGFC 1.37E-05 3.132188837 5.747502104 
226302_at ATP8B1 1.37E-05 4.729303393 2.953088663 
205992_s_at IL15 1.37E-05 5.108587768 3.02186665 
202411_at IFI27 1.37E-05 10.32098553 4.155674395 
205660_at OASL 2.00E-05 8.816232559 5.043755348 
201601_x_at NA 3.82E-05 9.514157211 6.172838679 
1553105_s_at DSG2 8.06E-05 3.716787789 7.380013058 
1555745_a_at LYZ 8.65E-05 3.657795152 8.966469996 
204156_at SIK3 0.000191614 3.014616564 5.596974796 
205883_at ZBTB16 0.000191614 3.9323087 6.382959729 
220773_s_at GPHN 0.000191614 3.965163502 6.331618458 
231955_s_at HIBADH 0.000191614 4.994812536 7.532474333 
205003_at DOCK4 0.000191614 6.547858789 4.336486424 
231504_at CCDC148 0.000191614 5.515141165 3.546226457 
228607_at OAS2 0.000191614 6.369024331 3.246325238 
208055_s_at HERC4 0.000210734 3.689389873 6.041702168 
209535_s_at NA 0.000283867 3.889135907 6.781673843 
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1555154_a_at QKI 0.000283867 4.751795874 7.783719526 
215991_s_at EMC1 0.000283867 2.249362269 3.683270007 
231274_s_at NA 0.000283867 3.425324062 5.435462999 
204698_at ISG20 0.000283867 8.165708071 5.327347603 
1554411_at CTNNB1 0.000376125 3.572852599 6.635933907 
219599_at EIF4B 0.000376125 4.228875606 7.030587927 
209055_s_at CDC5L 0.000376125 5.005916825 8.112529596 
220241_at TMCO3 0.000376125 3.662690418 5.589867462 
229787_s_at OGT 0.000598768 2.377767023 4.198765755 
221423_s_at YIPF5 0.000598768 4.764427984 7.983886289 
218031_s_at FOXN3 0.000598768 5.358068359 8.479315641 
227978_s_at ZADH2 0.000598768 4.560782669 6.978366066 
239827_at RGCC 0.000737413 2.922811434 4.531183441 
205552_s_at OAS1 0.000994295 8.52556634 4.199854718 
239131_at NA 0.001104595 2.869233639 4.766296652 
241699_at NA 0.001104595 2.524064046 3.903572868 
230265_at NA 0.001251697 3.971358386 7.268866264 
206420_at IGSF6 0.001251697 5.105353547 3.145928394 
213797_at RSAD2 0.001251697 7.200654765 4.091812827 
233878_s_at XRN2 0.001283386 4.250416536 8.047670115 
208047_s_at NAB1 0.001289249 2.984541409 4.570452219 
201295_s_at WSB1 0.001327936 3.992678087 7.276172187 
216015_s_at NLRP3 0.001658291 3.957640333 6.742987942 
205996_s_at AK2 0.001955832 6.117002334 9.595158229 
1552275_s_at PXK 0.002059935 4.965871756 8.855475104 
1569362_at ALCAM 0.002059935 2.854703141 4.974867187 
204426_at TMED2 0.002059935 4.787864769 8.339465929 
1555996_s_at NA 0.002059935 3.442752363 5.602525425 
215109_at RC3H1 0.002059935 3.362155971 5.244661583 
235306_at GIMAP8 0.002059935 4.411824265 2.656029179 
206544_x_at SMARCA2 0.00258171 4.255382491 7.791534959 
1555526_a_at 6-Sep 0.00258171 3.226981218 5.427391893 
243751_at CHD2 0.002932455 2.862859638 4.892477052 
224455_s_at ADPGK 0.002932455 4.545940524 7.377039775 
227404_s_at EGR1 0.002932455 6.017690069 9.554573831 
242277_at NA 0.004064267 2.948818284 4.971712234 
1554433_a_at ZNF146 0.004064267 4.586934708 7.705354771 
225742_at MDM4 0.004064267 3.634920337 5.721579115 
201075_s_at SMARCC1 0.004064267 5.677039327 8.919860071 
220220_at NA 0.004064267 2.721459192 4.259068431 
205746_s_at ADAM17 0.004064267 3.986940892 6.111574752 
232412_at FBXL20 0.004064267 3.011811652 4.544990573 
221039_s_at ASAP1 0.004609795 5.191490691 8.244705505 
224582_s_at NUCKS1 0.004609795 4.953985417 7.709158094 
239511_s_at SRSF4 0.004609795 2.671862785 4.037735602 
205321_at EIF2S3 0.009657355 4.505151046 9.214797982 
211089_s_at NEK3 0.009657355 3.153835382 5.417381302 
205123_s_at NA 0.009657355 3.148629261 5.292748903 
202269_x_at GBP1 0.009657355 5.830633782 3.51352209 
240771_at C1orf101 0.009657355 5.03064457 2.797264367 
203331_s_at INPP5D 0.009973264 4.808554468 7.500169639 
1570552_at NA 0.009973264 2.861867372 4.310545092 
239979_at NA 0.009973264 6.28946785 4.050437594 
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238511_at UBL7-AS1 0.014726225 3.881133701 6.361624354 
206785_s_at NA 0.014726225 4.160456492 2.549445938 
209754_s_at TMPO 0.017790649 3.93715112 6.449468774 
238846_at TNFRSF11A 0.017790649 4.856236144 3.122126895 
220735_s_at SENP7 0.02170125 2.719227978 4.817388541 
214908_s_at TRRAP 0.02170125 3.580343454 5.589555234 
233303_at NA 0.023432571 3.961680025 7.556922502 
231918_s_at GFM2 0.023432571 4.303872868 7.352626308 
210786_s_at FLI1 0.03509244 5.492847526 9.107798461 
216593_s_at PIGC 0.03509244 4.955690919 7.569466728 
229540_at RBPJ 0.03509244 3.648570198 5.510346371 
201971_s_at ATP6V1A 0.041216993 3.606919921 6.108703746 
227364_at NA 0.041216993 6.426258024 10.80594044 
222922_at KCNE3 0.041216993 2.993656568 4.937417089 
234977_at ZADH2 0.041216993 3.844053383 5.942264376 
227299_at CCNI 0.041216993 4.038234393 6.224050281 
207782_s_at PSEN1 0.041216993 4.654952249 7.164965461 
1553685_s_at SP1 0.041216993 3.317092537 5.001010317 
 
Table 5. THP-1 microarray (genes deregulated with >1.5-fold change, FDR<0.05) 
 
 
Gene Set Enrichment Analysis (GSEA) confirmed that ZNF521 depletion affected cell cycle 
progression and cell fate differentiation related genes (Brown, 2006) (Figure 16B,C). 
These results showed also positive enrichment of genes downregulated in CD133+ HSCs 
when compared with the CD133- cell (Jaatinen, 2006), and negative enrichment of 
embryonic stem cells (ESC) associated genes (Wong, 2008) (Figure 16D,E). The 
enrichment of stemness-related genes found by our analysis is in line with proposed role 
of ZNF521 in the regulation of hematopoietic stem cell homeostasis (Bond, 2008). 
Furthermore, GSEA revealed a negative enrichment with genes that are upregulated in 
MLL-rearranged pediatric AML compared with non-MLL-rearranged AML (Mullighan, 
2012) (Figure 16F,G). Interestingly, the ZNF521 depletion gene set revealed positive 
enrichment with genes that are upregulated in hematopoietic precursors conditionally 
expressing HOXA9 and MEIS1, including HOXA9 target genes upregulated in 
hematopoietic stem cells (Dorsam, 2004; Hess, 2006) (Figure 16H,I). In addition, genes 
up-regulated or downregulated upon knockdown of HOXA9 (Faber, 2009) were also 
similarly regulated in ZNF521-transduced THP-1 cells (Figure 16J,K).  
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FIGURE 16. Microarray results of ZNF521 depletion in THP-1 cells. (A) Hierarchical clustering analysis of 
differently gene expression profiles associated with transduced THP-1 cells with ZNF521 shRNA (ZNF004) 
or control shScram after 4 days of transduction. Each column represents a sample and each row represent 
a gene. Relative levels of gene expression are depicted with a color scale where red represents the highest 
level of expression and green represents the lowest level. (B-E) GSEA plot showing gene expression 
signature of (B) negative enrichment of cell cycle signature, (C) negative enrichment of downregulated 
genes in myeloid cell development signature, (D) positive enrichment of downregulated genes in HSCs 
signature and (E) negative enrichment of embryonic stem cell core signature. (F,G) GSEA plot showing 
negative enrichment of MLL signature up-regulated genes in pediatric AML. (H-K) GSEA showing 
enrichment of upregulated genes in HOXA9 up-regulated (H) and down-regulated (I) signatures in HOXA9 
knockdown cells, (J) positive enrichment of HOXA9 targets up-regulated and (K) negative enrichment of 
HOXA9 targets down-regulated in hematopoietic stem cells. The normalization enrichment score (NES) and 
the false discovery rate (FDR) values are indicated in each panel. Red and blue color bars indicated the 
positive and negative enrichment, respectively. 
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Considering individual genes, we found deregulated genes with known relevance in MLL-
fusion-mediated AML (TET1, CDK6 and Musashi2) (Huang, 2013; Placke, 2014; Park, 
2015) and in myeloid progenitors differentiation (CD14 and MEF2A) (Zheng, 2015) 
(Figure 17).  
 
 
 
 
Figure 17. Dot-plots of expression of CDK6, Msi2, TET1, CD44 and MEF2A genes selected from the 
microarray data of transduced THP-1 cells with ZNF521 shRNA (ZNF004) or shScram. FDR, false discovery 
rate. 
Taken together, these results indicate that ZNF521 expression negatively modulates 
genes involved in myeloid differentiation, and is required to maintain expression 
programs associated with MLL-induced transformation. 
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7. ZNF521 GENE PROMOTER IS ACTIVATES BY MLL FUSION PROTEINS.  
 
Finally, to investigate the molecular mechanism that upregulates ZNF521 in MLL-
rearranged AML, we performed luciferase reporter and ChIP assays using the Flag-tagged 
MLL-AF9 expression plasmid. To this end, we generated a series of constructs in which 
5.0 kb of the genomic region upstream of the ZNF521 transcription start site (TSS) was 
subdivided in 4 fragments (ZNF521P1, ZNF521P2, ZNF521P3 and ZNF521P4) and inserted 
into a pGL4-basic reporter plasmid (Figure 18A). Luciferase assays in 293T cells showed 
that MLL-AF9 strongly activated the promoter region that lay between -1.3 to -3 kb 
(ZNF521P3) of the TSS (Figure 18A). To further confirm the region of ZNF521 activated by 
MLL-AF9, we generated 3 constructs (ZNF521P3.1, ZNF521P3.2 and ZNF521P3.3) 
spanning the ZNF521P3 fragment (Figure 18B). We found that the pGL4-ZNF521P3.3 
construct showed the highest luciferase activity (Figure 18B), indicating that the MLL-AF9 
responsive elements likely reside between -1.0 and -1.6 kb upstream of the ZNF521 TSS. 
Furthermore, to determine whether ZNF521 activation was MLL fusion-dependent, we 
performed ZNF521-driven luciferase reporter assay in another MLL fusion gene (MLL-
ENL) and in two non-MLL-associated fusion genes such as AML1-ETO and PML-RARAα. 
We observed that both AML1-ETO and PML-RARAα yielded only a minimal luciferase 
activity compared with MLL-ENL that showed even a higher promoter binding affinity 
than MLL-AF9 (>2.5 fold) (Figure 18C). Besides, wild-type (WT) MLL did not affect 
luciferase activity under the same settings, providing evidence that only MLL-fusion 
proteins likely activate ZNF521 expression (Figure 18C). Consistent with these results, 
ChIP analyses showed that both MLL-AF9 and MLL-ENL bind to ZNF521 promoter region 
in transfected 293T cells (Figure 18D). In order to validate MLL-AF9 binding to the 
ZNF521 promoter in AML cells, we performed ChIP with lysate from NOMO-1 and HL60 
cell lines that endogenously expressing MLL-AF9 and WT MLL, respectively. Since that 
MLL-AF9 lacks the MLL-C portion of WT MLL, an anti-MLL N-terminal (MLLN) and an anti-
MLL C-terminal (MLLC) antibodies were used for this experiment. ChIP assays showed 
that MLLN bound specifically to the ZNF521 promoter region in NOMO-1 but not in HL60 
(Figure 18E; upper panel). By contrast, there was not apparently association with MLLC 
and ZNF521 in both NOMO-1 and HL60 cells (Figure 18E; lower panel). Together, these 
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findings demonstrated that ZNF521 promoter is specifically bound by MLL-AF9, and 
provide further evidence that MLL fusion oncoproteins may drive aberrant expression of 
ZNF521, which may in turn lead to a block in differentiation. 
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FIGURE 18. MLL-AF9 and MLL-ENL fusion oncoproteins bind to ZNF521 promoter. (A) An illustration of the 
4 fragments representing 5058 bp of ZNF521 promoter and their positions are indicated in the left panel. 
The numbers above each part are referred to the length (bp) of the genomic fragment that was PCR 
amplified and then cloned upstream of the luciferase coding sequence (luc) of PGL42.8 plasmid. In the 
right panel, horizontal bars represent the luciferase activity generate by each construct following transient 
transfection in 293T cells with MLL-AF9 plasmid. (B) An illustration of the 3 fragments of ZNF521P3 and 
their respective positions are shown in the left panel. The numbers above each part are referred to the 
length (bp) of the genomic fragment cloned into PGL42.8 plasmid. In the right panel, horizontal bars 
represent the luciferase activity generate by each construct as described in A. (C) Luciferase activity of the 
ZNF521P3.3 fragment after transient transfection in 293T cells with AML1-ETO, PML-RARα, wild-type (WT) 
MLL, MLL-ENL or MLL-AF9 is shown. For each panel (A, B and C), luciferase activity is expressed relative to 
the empty vector of each expression plasmid (white bars) and normalizes to Firefly/Renilla luciferase 
activities considering the empty pGL42.8 vector as 1. Data are represented as mean ± SD of three 
independent experiments. (D) Both MLL-AF9 and MLL-ENL fusion oncogenes associates with the 
ZNF521P3.3 promoter region. ChIP assays were performed with the crossed-linked genomic DNA isolated 
from 293T cells transfected with either Flag-MLL-AF9 or Flag-MLL-ENL and using anti-Flag and anti-IgG 
antibodies. Normal IgG was used as a negative control. Input DNA from sonicated chromatin and 
immunoprecipitated DNA were subjected to PCR amplification with primers spanning the ZNF521P3.3 
promoter region. PCR amplification with primers specific to the HOXA9 promoter region was used as 
positive control. Data from a representative of three replicate experiments are shown. (E) ChIP analysis of 
the ZNF521P3.3 promoter in NOMO-1 cells, which express MLL-AF9 and HL60 cells, which express WT MLL 
but not MLL-AF9, using antibodies directed to the N-terminus of MLL (MLLN; upper panel), C-terminus of 
MLL (MLLC; lower panel) or IgG. Immunoprecipitated chromatin samples were analyzed by PCR using 
primers corresponding to promoter ZNF521P3.3 region. Note that no PCR product for ZNF521 promoter 
was obtained when anti-MLLC, which recognizes only the WT MLL but not MLL-AF9, was used for 
immunoprecipitation.  
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DISCUSSION 
 
 
ZNF521 is a gene that showed a significant higher level of expression in MLL-related AML 
so as in HSCs and can be used as a marker. In this work, I present data showing that 
pediatric AML patients carrying MLL translocations have a significantly upregulation of 
ZNF521 expression independently of the fusion partner involved in the translocation 
with MLL. The overexpression of ZNF521 is a robust transcriptional feature of MLL-
rearranged AML, consistent across independent adult and pediatric microarray datasets 
(Kohlmann, 2009; Jo, 2009; Pigazzi, 2011). From these data, I started my study with the 
aim to decrypt the ZNF521 function as transcription factor in MLL-rearranged AML, and 
understand if it might deserve attention as potential therapeutic target.  
A major hallmark of leukemia and a consequence of MLL fusion proteins expression is a 
block in hematopoietic differentiation (Huntly, 2005). On this way, my data show that 
the most relevant effect of ZNF521 depletion was to enhance myeloid differentiation of 
leukemia cells as evidenced by changes in cell morphology, immunophenotype and 
increase of a myeloid-specific gene expression in MLL-rearranged cell lines and primary 
cells. The requirement of ZNF521 in the maintenance of an undifferentiated status 
associated with MLL-rearranged AML was also supported by the fact that ZNF521 
expression drastically decreased upon treatment with specific differentiation-induced 
agents, such as ATRA. The observed growth defect, cell cycle arrest and reduced colony 
formation upon ZNF521 depletion were secondary to cells entering into a differentiation 
program. Thus, MLL fusion proteins might promote leukemogenesis not only by HOXA9 
and MEIS1 upregulation, but also by keeping the ZNF521 overexpressed, which in turn 
contributes to a block of differentiation or to the maintenance of an undifferentiated 
state of leukemia cells.  
Consistent with this finding, others have reported that loss of ZNF521 enhanced 
erythroid differentiation and increased B-lineage maturation in cell lines and primary 
hematopoietic progenitor cell, respectively (Matsubara, 2009; Mega, 2011). Moreover, it 
is well established that Zfp521, the mouse counterpart of human ZNF521, in other 
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cellular contexts including, embryonic stem cells (ESCs), neural cells, osteoblasts and 
chondrocytes mainly function to control cell differentiation of primitive or mature cells 
by modulating the activity of specific transcription factors [46-49]. Consistent with these 
findings, our GSEAs in THP-1 cells depleted for ZNF521 showed enrichment of 
hematopoietic stem cells (HSCs)- and ESC-associated downregulated genes and sets of 
genes associated with differentiation program (Brown, 2006; Jaatinen, 2006). Based on 
these findings, we assumed that ZNF521 has not only a role in promoting self-renewal 
and maintenance of HSCs but it also acts in MLL rearranged AML. Furthermore, the 
results support the direct activation of ZNF521 by MLL fusion proteins increasing the 
importance of this transcription factor in the transformation of the leukemia cells. In 
fact, it is showed enrichment of set of genes related to MLL fusion-dependent 
transformation signatures as well as to HOXA9-mediated gene expression program 
(Dorsam, 2004; Faber, 2009; Mullighan, 2015). Thus, the events documented after 
ZNF521 depletion, which in part resemble what has been previously observed in MLL-
rearranged cells after loss of HOXA9, gave a further support that ZNF521 plays a critical 
role in MLL-fusion-mediated leukemia. Interestingly, the expression of either HOXA9, a 
canonical downstream target for MLL-rearranged leukemia (Ayton, 2003; Argiropoulos 
2007) or ZNF521 have been shown to be restricted to CD34+ progenitor cells (Dorsam, 
2004; Bond, 2008; Mullighan, 2012). Nevertheless, in gene-expression analysis, loss of 
ZNF521 does not affect HOXA9 expression, implying that both are MLL-dependent but 
might act in a non-mutually exclusive and additive manner. Supporting the idea that 
ZNF521 is particularly required for MLL-mediated leukemia, the data of luciferase 
reporter and ChIP assays revealed that ZNF521 is a direct target of both MLL-AF9 and 
MLL-ENL fusion proteins. We defined a genomic region of 555 bp in 5’ ZNF521 promoter 
that is thought to be crucial for ZNF521 activation by MLL fusion proteins.  
This finding is consistent with prior observations that showed how the modulation of 
MLL-AF9 levels resulted in concordant changes in ZNF521 expression in different human 
in vitro models (Abdul-Nabi, 2010; Fleischmann, 2014). Surprisingly, the inspection of 
ChIP-seq data from Bernt et al, (Bernt, 2011) did not show peak in the vicinity of the 
Zfp521 gene in an MLL-AF9 mouse leukemia model. Of note, this is also observed for 
other well-known targets of MLL fusion proteins such as EVI1 and PLZF (Arai, 2011; Ono, 
2013). About ZNF521, this can be explained by the different approaches used, and the 
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fact that in mouse BM Zfp521 is primarily expressed in the HSC fraction and significantly 
reduced in granulocyte-monocyte-progenitor cells (GMPs) 
(http://servers.binf.ku.dk/bloodspot/?gene=ZFP521&dataset=nl_mouse_data), in which 
the analysis has been done. Future ChIP-seq experiments on human transformed HSC 
will likely shed further light on ZNF521-MLL-AF9 target gene specificity. 
In summary, this study unravels the anti-differentiation function of ZNF521 in MLL-
rearranged cells and showed the mechanism by which ZNF521 participates in MLL-fusion 
mediated transformation. This data also indicate that ZNF521 is highly expressed in the 
majority of MLL-rearranged AML pediatric patients, and thus ZNF521 could be a 
potential molecular target for this subtype of aggressive leukemia. 
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